

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 211/18, 211/40, 211/86 C07D 401/06, 401/14, 417/06		A1	(11) International Publication Number: WO 92/19595 (43) International Publication Date: 12 November 1992 (12.11.92)
(21) International Application Number: PCT/US92/03463 (22) International Filing Date: 27 April 1992 (27.04.92) (30) Priority data: 696,893 7 May 1991 (07.05.91) US 720,357 25 June 1991 (25.06.91) US 871,262 23 April 1992 (23.04.92) US (71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: DUGGAN, Mark, E. ; 300 North Essex Avenue, Apt. 205B, Narberth, PA 19072 (US). HARTMAN, George ; 1529 Tennis Circle, Lansdale, PA 19446 (US). EGBERTSON, Melissa, S. ; 1232 Lois Road, Ambler, PA 19002 (US). IHLE, Nathan ; 2416 Rickert Road, Perkasie, PA 18944 (US). TURCHI, Laura, M. ; 214 Croft Ridge Drive, Broomall, PA 19008 (US). HOFFMAN, William, F. ; 740 Weikel Road, Lansdale, PA 19446 (US).		(74) Agent: PARR, Richard, S.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: BG, CS, FI, HU, NO, PL, RO, RU. Published With international search report.	

(54) Title: FIBRINOGEN RECEPTOR ANTAGONISTS



(57) Abstract

Fibrinogen receptor antagonists of formula (I) are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TC	Togo
DK	Denmark			US	United States of America

5

- 1 -

10 TITLE OF THE INVENTION
FIBRINOGEN RECEPTOR ANTAGONISTS

CROSS-REFERENCES

15 This application is a continuation-in-part
of U.S. Serial No. 720,357, filed June 25, 1991,
which is a continuation-in-part of U.S. Serial No.
696,893, filed May 7, 1991.

20 FIELD OF THE INVENTION

This invention relates to the discovery of
fibrinogen receptor antagonists of Formula I for use
in inhibiting the binding of fibrinogen to blood
platelets and inhibiting the aggregation of blood
platelets when administered to mammals, preferably
25 humans.

BACKGROUND OF THE INVENTION

The interaction of platelets with the
coagulation and fibrinolytic systems in the
30 maintenance of hemostasis may become pathogenic,

- 2 -

requiring prevention and treatment. The fibrinogen receptor antagonists of Formula I are useful in treating various diseases related to platelet aggregation and fibrin formation.

5 An interest in platelet inhibitors has reemerged as a result of a better understanding of the role of platelets and thrombosis in the pathogenesis of vascular disease, including unstable angina, acute myocardial infarction and stroke.

10 Platelets are cell-like anucleated fragments, found in the blood of all mammals, which participate in blood coagulation. Fibrinogen is a glycoprotein present as a normal component of blood plasma. Fibrinogen participates in platelet
15 aggregation and fibrin formation in the blood clotting mechanism. Platelets are deposited at sites of vascular injury where multiple physiological agonists act to initiate platelet aggregation culminating in the formation of a platelet plug to minimize blood
20 loss. If the platelet plug occurs in the lumen of a blood vessel, normal blood flow is impaired.

 Platelet membrane receptors are essential in the process of platelet adhesion and aggregation. Interaction of fibrinogen with a receptor on the
25 platelet membrane complex IIb/IIIa is known to be essential for normal platelet function.

 Zimmerman et al., U.S. Patent No. 4,683,291, describes peptides having utility in the study of
30 fibrinogen-platelet, platelet-platelet, and cell-cell interactions. The peptides are described as having utility where it is desirable to retard or prevent formation of a thrombus or clot in the blood.

- 3 -

Pierschbacher et al., U.S. Patent No. 4,589,881, describes the sequence of an 11.5 kDal polypeptide fragment of fibronectin which embodies the cell-attachment-promoting activity of fibronectin.

5 Ruoslahti et al., U.S. Patent No. 4,614,517, describes tetrapeptides which alter cell-attachment activity of cells to various substrates. Figure 1 lists the polypeptides that were synthesized by Ruoslahti et al. in "determining the smallest peptide
10 exhibiting cell attachment activity." Ruoslahti et al., U.S. Patent No. 4,578,079, describes similar tetrapeptides.

 Pierschbacher et al., Proc. Natl. Acad. Sci. USA, Vol. 81, pp.5985-5988, October, 1984, describe
15 variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Pierschbacher et. al. further assayed the cell attachment-promoting activities of a number of structures closely resembling the Arg-Gly-Asp-Ser
20 peptide, and found "that the arginine, glycine, and aspartate residues cannot be replaced even with closely related amino acids, but that several amino acids can replace serine without loss of activity."

 Ruoslahti et al., Science, Vol. 238, pp. 491-497, October 23, 1987, discuss cell adhesion
25 proteins. They specifically state that "elucidation of the amino acid sequence of the cell-attachment domain in fibronectin and its duplication with synthetic peptides establish the sequence Arg-Gly-Asp
30 (RGD) as the essential structure recognized by cells in fibronectin."

- 4 -


Cheresh, Proc. Natl. Acad. Sci. USA, Vol. 84,
pp. 6471-6475, September 1987, describes the
Arg-Gly-Asp-directed adhesion receptor involved in
attachment to fibrinogen and the von Willebrand
Factor.

Adams et al., U. S. Patent No. 4,857,508,
describes tetrapeptides which inhibit platelet
aggregation and the formation of a thrombus.

It is, therefore, an object of the present
invention to provide fibrinogen receptor antagonists
for use in inhibiting the binding of fibrinogen to
blood platelets and inhibiting the aggregation of
blood platelets. Another aspect of the present
invention is to provide novel fibrinogen receptor
antagonist compounds. Other objects of the present
invention are to provide methods of inhibiting the
binding of fibrinogen to blood platelets and
inhibiting the aggregation of blood platelets,
through the administration of novel fibrinogen
receptor antagonist compounds. The above and other
objects are accomplished by the present invention in
the manner described below.

SUMMARY OF THE INVENTION

The present invention provides fibrinogen
receptor antagonist compounds of the formula:




I

- 5 -

for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets. The above-mentioned compounds can be used in a method of acting upon a fibrinogen receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, dispersed therein, an effective but non-toxic amount of such compound is another feature of this invention.

DETAILED DESCRIPTION OF THE INVENTION

Fibrinogen receptor antagonist compounds of Formula I are useful in a method of inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets. Fibrinogen receptor antagonists of this invention are illustrated by compounds having the formula:




I


- 6 -

wherein:


X is




5




10




15



20





25



30

- 7 -

Y is



where R^{10} is C_{1-8} alkyl, aryl, aryl C_{1-8} alkyl;

u is $-\text{CH}-$, $-\text{C}-$, or $-\text{N}-$;

v is $-\text{CH}-$, $-\text{C}-$, or $-\text{N}-$;

20 R and R^1 are independently
hydrogen,

aryl, wherein aryl is defined as a mono- or polycyclic aromatic system comprised of 5 or 6 membered rings containing 0, 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen and sulfur; and phenylene, either unsubstituted or substituted, with one or more groups selected from hydroxyl, fluoro, chloro, bromo, iodo, cyano, trifluoromethyl, C_{1-3} alkoxy, C_{1-5} alkylcarbonyloxy, C_{1-5} alkoxy carbonyl, C_{1-5} alkyl, amino C_{1-5} alkyl, hydroxycarbonyl C_{0-5} alkyl, or hydroxycarbonyl C_{1-5} alkoxy,

25

30


- 8 -

C₀₋₆alkyl, either unsubstituted or substituted, with one or more groups selected from fluoro, chloro, bromo, iodo, hydroxyl, C₁₋₅alkylcarbonyl-
5 (C₀₋₈alkyl)amino, arylC₁₋₅alkyl carbonyl(C₀₋₈alkyl)amino, aryloxy, C₁₋₁₀alkoxy, C₁₋₅alkoxycarbonyl, C₀₋₅alkylaminocarbonyl, C₁₋₅ alkyl-carbonyloxy, C₃₋₈cycloalkyl, aryl, oxo,
10 amino, C₁₋₆alkyl, C₁₋₃alkylamino, aminoC₁₋₃alkyl, arylC₀₋₅alkylamino-carbonyl, phenylC₁₋₃ alkylamino, amino-carbonylC₀₋₄alkyl, C₁₋₈alkyl-sulfonyl (C₀₋₈alkyl)amino, arylC₀₋₁₀-
15 alkylsulfonyl(C₀₋₈alkyl)-alkylsulfonyl, C₀₋₈alkylsulfonyl, hydroxycarbonyl-C₀₋₅alkyl, C₁₋₈alkyloxycarbonyl-(C₀₋₈alkyl)amino, arylC₀₋₁₀alkyloxy-carbonyl(C₀₋₈alkyl)amino, C₀₋₈
20 alkylaminocarbonyl(C₀₋₈ alkyl)amino, arylC₀₋₈alkylaminocarbonyl(C₀₋₈-alkyl)amino, C₀₋₈alkylaminocarbonyloxy, arylC₀₋₁₀alkylaminocarbonyloxy, C₀₋₈-alkylaminosulfonyl(C₀₋₈ alkyl)amino,
25 arylC₀₋₈alkylaminosulfonyl(C₀₋₈alkyl)amino, C₀₋₈alkylaminosulfonyl, or arylC₀₋₈alkylaminosulfonyl;
provided that the carbon atom to which
30 R or R¹ is attached bear only one heteroatom;

- 9 -

R² is hydrogen,
C₁₋₁₂alkyl, unsubstituted or substituted,
with one or more C₁₋₆alkyl groups,

5



10

where R⁹ = C₁₋₆alkyl, branched or
unbranched, or phenyl, and wherein R⁹, when
appearing more than once, can be same or
different;


R⁷, R³ and R⁴ are independently
hydrogen,

15

C₁₋₁₂ alkyl, unsubstituted or substituted,
with one or more C₁₋₆ alkyl
groups,
arylC₀₋₄alkyl, or
cyano

20

provided that when R⁷ and R³
are independently cyano, X



25

k is 1-4;

m is 1-4;

p is 1-6;


q is 0-2;

30

or the pharmaceutically acceptable salts thereof, or
optical isomers thereof.




- 10 -

More preferred compounds of the present invention have the following formula:




I

wherein:



Z is CO_2R^2

25 Y is



- 11 -

wherein n is 1, 2 or 3;

R and R¹ are independently chosen from phenyl,

thiophene, imidazole, naphthyl, indole,

indazole, thionaphthene, either unsubstituted

5 or substituted, with hydroxy, halogen, hydroxy-

carbonyl C₀₋₅ alkyl, C₁₋₃alkyl, either

unsubstituted or substituted, with one or more

groups selected from aryl, aryloxy, C₁₋₁₀

10 alkoxy, C₀₋₅ alkylaminocarbonyl, arylC₀₋₅

alkylaminocarbonyl,

hydrogen,

C₀₋₆alkyl either unsubstituted or substituted,

with one or more groups selected from halogen,

hydroxyl, C₁₋₆alkylsulfonylamino, aryl

15 C₀₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl,

arylC₀₋₆alkylsulfonyl, C₁₋₅alkylcarbonylamino,

arylC₁₋₅alkylcarbonylamino, aryloxy, C₁₋₁₀

alkoxy, C₁₋₅alkoxycarbonyl, C₀₋₅alkylamino-

carbonyl, C₁₋₅alkylcarbonyloxy, C₃₋₈cycloalkyl,

20 aryl, oxo, amino, C₁₋₆alkyl, C₁₋₃alkylamino,

aminoC₁₋₃ alkyl, arylC₀₋₅ alkylaminocarbonyl,

phenylC₁₋₃ alkylamino, aminocarbonylC₀₋₄ alkyl,

or hydroxycarbonylC₀₋₅ alkyl, provided that

the carbon atom to which R or R¹ is attached

25 bear only one heteroatom,


R² is hydrogen,

C₁₋₁₂ alkyl, unsubstituted or substituted,

with one or more C₁₋₆alkyl groups,

30

- 12 -



5 where $\text{R}^9 = \text{C}_{1-6}\text{alkyl}$, branched or unbranched, or phenyl, and wherein R^9 , when appearing more than once, can be the same or different;

R^7 , R^3 and R^4 are independently hydrogen, or
 10 $\text{C}_{1-3}\text{alkyl}$, unsubstituted or substituted, with one or more $\text{C}_{1-6}\text{alkyl}$ groups;

k is 1-4;


m is 1-4;

q is 0 or 2;

15 p is 1-3;


or the pharmaceutically acceptable salts thereof, or optical isomers thereof.

20 Most preferred compounds of the present invention have the following formula:



I

25 X is




- 13 -


 $-NR^7R^3;$ where D = -O-, -S-, or $-\overset{\overset{O}{\parallel}}{C}-$,Z is CO_2R^2

5 Y is


10



15



or



wherein n is 1, 2 or 3;

20 R and R^1 are independently chosen from phenyl,
 thiophene, imidazole, naphthyl, indole,
 indazole, thionaphthene, either unsubstituted
 or substituted, with hydroxy, halogen, hydroxy-
 carbonyl C_{0-5} alkyl, C_{1-3} alkyl, either
 unsubstituted or substituted, with one or more
 25 groups selected from aryl, aryloxy, C_{1-10}
 alkoxy, C_{0-5} alkylaminocarbonyl, aryl C_{0-5}
 alkylaminocarbonyl,
 hydrogen,
 C_{0-6} alkyl, either unsubstituted or substituted,
 30 with one or more groups selected from halogen,
 hydroxyl, C_{1-5} alkylcarbonylamino, aryl C_{1-5}
 alkylcarbonylamino, aryloxy, C_{1-10} alkoxy,
 C_{1-5} alkoxy carbonyl, C_{0-5} alkylaminocarbonyl,

- 14 -

C₁₋₅alkylcarbonyloxy, C₃₋₈cycloalkyl, aryl, oxo, amino, C₁₋₆alkyl, C₁₋₃alkylamino, aminoC₁₋₃ alkyl, arylC₀₋₅ alkylaminocarbonyl, phenylC₁₋₃ alkylamino, aminocarbonylC₀₋₄ alkyl, or hydroxycarbonylC₀₋₅ alkyl, provided that the carbon atom to which R or R¹ is attached bear only one heteroatom;

R² is hydrogen;

R⁷, R³ and R⁴ are

hydrogen;

m is 1-4;

p is 2-4;

or the pharmaceutically acceptable salts thereof, or optical isomers thereof.

This invention includes the following abbreviation designations; Bn, benzyl; NMM, N-methylmorpholine; HOBT, 1-hydroxybenzotriazole; EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-hydrochloride; DMF, dimethylformamide; BOC, tert-butyloxycarbonyl; pTSA, para-toluenesulfonic acid; DMS, dimethylsulfide; TFA, trifluoroacetic acid; THF, tetrahydrofuran; TBDMS, tert-butyldimethylsilyl.

The pharmaceutically acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of Formula I formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric,

- 15 -

hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

The pharmaceutically acceptable salts of the acids of Formula I are also readily prepared by conventional procedures such as treating an acid of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzyl-ethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.

The compounds of Formula I are useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood

- 16 -

platelets, treatment of thrombus formation or embolus formation, in the prevention of thrombus formation or embolus formation, and in the mediation of cell-cell fusion events, such as sperm-egg fusion, resulting in mammalian fertilization inhibition. These compounds are useful as pharmaceutical agents for mammals, especially for humans. The compounds of this invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. Compounds of this invention may also be used to prevent or modulate the progress of myocardial infarction, unstable angina and thrombotic stroke, in either acute or chronic settings. In addition, they may be useful in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and thromboemboli. Compounds of this invention may be administered to surgical patients to prevent the formation of thrombi and thromboemboli.

Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between GPIIb/IIIa on the platelet membranes and fibrinogen adsorbed to the surface of the circuit. (Gluszko et al., Amer. J. Physiol., 1987, 252:H, pp 615-621). Platelets released from artificial surfaces show impaired

- 17 -

hemostatic function. Compounds of this invention may be administered to prevent adhesion.

Other applications of these compounds include prevention of platelet thrombosis, thromboembolism, reocclusion, and restenosis during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism, reocclusion and restenosis after angioplasty of coronary and other arteries and after coronary artery bypass procedures.

The compounds of Formula I may be administered to mammals, preferably in combination with pharmaceutically-acceptable carriers or diluents, optionally with known adjuvants such as alum, in a pharmaceutical composition which is non-toxic and in a therapeutically effective amount, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, trans-dermal, subcutaneous and topical administration.

For oral use of a fibrinogen receptor antagonist according to this invention, the selected compounds may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active

- 18 -

ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.

5 For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in
10 order to render the preparation isotonic.

The present invention also encompasses a pharmaceutical composition useful in the treatment and prevention of diseases related to platelet aggregation, fibrin formation, and thrombus and
15 embolus formation, comprising the administration of a therapeutically effective but non-toxic amount of the compounds of Formula I, with or without pharmaceutically acceptable carriers or diluents.

Compositions of this invention include
20 fibrinogen receptor antagonist compounds of this invention in combination with pharmacologically acceptable carriers, e.g. saline, at a pH level e.g. 7.4, suitable for achieving inhibition of platelet aggregation. The compositions may also be combined
25 with anticoagulants such as heparin or warfarin. The compositions may also be combined with thrombolytic agents such as plasminogen activators or streptokinase in order to inhibit platelet aggregation in more acute settings. The composition
30 may further be combined with antiplatelet agents such as aspirin. The compositions are soluble in an aqueous medium, and may therefore be effectively administered in solution.

- 19 -

When a compound according to Formula I is used as a fibrinogen receptor antagonist in a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patients symptoms.

In one exemplary application, a suitable amount of compound is administered orally to a heart attack victim before or subsequent to angioplasty. Administration occurs before or subsequent to angioplasty, and is in an amount sufficient to inhibit platelet aggregation, e.g. an amount which achieves a steady state plasma concentration of between about 0.01-100 μM preferably between about 0.01-10 μM .

The present invention also includes a pharmaceutical composition comprising compounds of the present invention in combination with tissue type plasminogen activator or streptokinase. The invention also includes a method for promoting thrombolysis and preventing reocclusion in a patient which comprises administering to the patient an effective amount of compositions of the invention.

The present invention provides a method of inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood platelets, treating thrombus formation or embolus formation, and in preventing thrombus formation or embolus formation in a mammal, comprising the administration of a therapeutically effective but non-toxic amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.

- 20 -

The present invention still further provides a method of inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood platelets, treating thrombus formation or embolus formation, and in preventing thrombus formation or embolus formation in a mammal, comprising the administration of a therapeutically effective but non-toxic amounts of the compounds of this invention in combination with thrombolytic agents, such as tissue plasminogen activators or streptokinase, anticoagulants such as heparin or warfarin, or antiplatelet agents such as aspirin, with or without pharmaceutically acceptable carriers or diluents.

15

20

25

30


- 21 -

The following compounds and associated IC₅₀ values (concentrations which inhibit aggregation by 50% relative to a control lacking the compound) are exemplary of the invention.


5

CompoundIC₅₀


10

0.097 μ M

15

0.031 μ M

20

100 μ M


25

30


- 22 -

IC₅₀

5


0.016 μ M

10

1.4 μ M

15

20

0.2 μ M


25

30


- 23 -

IC₅₀


5

0.037 μ M


10

7.8 μ M

15

0.011 μ M





20

0.03 μ M





25

30

- 24 -


		<u>IC₅₀</u>
5		0.18 μM
10		0.056 μM
15		
20		17 μM
25		
30		0.55 μM

- 25 -

		<u>IC₅₀</u>
5		0.096 μ M
10		0.14 μ M
15		
20		8.1 μ M
25		0.84 μ M
30		

- 26 -


5



IC₅₀

0.27 μ M


10



0.028 μ M


15

20



3.7 μ M

25




0.83 μ M

30

- 27 -


IC₅₀

5




0.58

10

0.2 μ M

15

20


0.39 μ M

25


30

- 28 -


5

 IC_{50} 0.42 μM

10

3.1 μM

15

0.55 μM

20

25

30

- 29 -

Compounds of the invention can be prepared according to one of the following general procedures:

SCHEME 1

5 An aryl or alkyl alcohol is protected if needed and is oxidized to the corresponding aldehyde via oxalyl chloride/DMSO, pyridinium chlorochromate or similar reagent. Typically, these oxidations are carried out in halocarbon solvents such as CH_2Cl_2 at
10 -78° to room temperature for 0.5-6 hrs. Olefination of the resulting aldehyde with a carboalkoxymethylene phosphorane proceeds to give the desired unsaturated ester. Typically, this reaction is run in halocarbon solvents such as CH_2Cl_2 at $0-60^\circ$ for 1-18 hours.
15 Treatment of this ester with a chiral amine such as R-(+)- α -methylbenzylamine provides a diastereomeric mixture of amines that can be separated typically by column chromatography.

20

SCHEME 2

 An aminoalkanol is protected on N with a BOC, or similarly suitable group such as CBZ, FMOC, etc., and converted to the alkyl halide, typically the iodide. Ph_3P and iodine are typically used for
25 this purpose and the reaction is run in aromatic solvents such as benzene or toluene in halocarbons such as CH_2Cl_2 at $0-50^\circ$ for 5 minutes to 10 hrs. Formation of an alkyl azide is effected by treatment with NaN_3 or similar azide transfer agent, and this
30 azide is catalytically reduced to the corresponding amine in alcohol solvents (EtOH , CH_3OH) at room temperature over the course of 0.5-10 hrs.


- 30 -

SCHEME 3


Alkylation of cyclic amide or urea intermediates occurs in the presence of a suitable base, such as $\text{LiN}(\text{TMS})_2$ or simple amines such as $\text{EtN}(\text{i-Pr})_2$ and an appropriate alkylating agent such as an alkyl iodide or a bromide such as ethyl bromoacetate. Disubstitution in the intermediate is effected by repetition of the deprotonation/alkylation sequence. When an allyl reagent is used to alkylate, subsequent oxidation with $\text{RuCl}_3/\text{NaIO}_4$ or KMnO_4 or other suitable reagent provides the terminal carboxylic acid. This acid may then be coupled via an amide bond with C-terminal chiral or achiral amines to provide further intermediates. Typically, coupling reactions are carried out in DMF or halocarbon solvents such as CH_2Cl_2 utilizing standard reagents such as DCC, EDC, i-butyl chloroformate and the like. Final de-protection of intermediates typically involves base catalyzed hydrolysis of esters and acid catalyzed N-deprotection.

The compounds of Formula I are prepared according to the reaction schemes set forth below. Compound 1, 3-indolepropanol, is commercially available from Aldrich Chemical.

- 31 -


SCHEME 1

- 32 -

SCHEME 1 cont'd


Compound 8 is commercially available from American
Tokyo Kansei, Inc.

- 33 -

SCHEME 2

- 34 -


SCHEME 3



- 35 -

SCHEME 3 cont'd


5



10

1N NaOH, ethanol


15



20

TFA, CH₂Cl₂, anisole, -15°C


25




30

- 36 -


SCHEME 4



- 37 -

SCHEME 4 cont'd

10
↓
1N NaOH, ethanol




25

30

- 38 -


SCHEME 4 cont'd23TFA, CH_2Cl_2

-15°C, anisole

24

- 39 -


SCHEME 5



- 40 -

SCHEME 5 cont'd


5



10

1 N NaOH, ethanol


15



20

TFA, CH₂Cl₂, anisole


25



30

- 41 -

SCHEME 6



- 42 -

SCHEME 6 cont'd

5


10

15

20


25

30



- 43 -

SCHEME 6 cont'd




- 44 -

SCHEME 6 cont'd

5


38bEDC, HOBT, NEt_3 , DMF, 7a

10

39b

1N NaOH ethanol


15

40b

20


TFA, CH_2Cl_2 , anisole, -15°C

25

41b

30

SCHEME 7



SCHEME 7 (continued)

5


10

15




20

25

30



SCHEME 7 (continued)




5
10
15
20
25
30



- 49 -


SCHEME 9




- 50 -

SCHEME 9 CONT'D.

5

761 N NaOH CH₃OH


10

77

15

CF₃CO₂H CH₂Cl₂

20

78

25

30

- 51 -

SCHEME 10

5


10

15


20

25

30




- 52 -



SCHEME 10 CONT'D.

- 53 -

SCHEME 11




- 54 -

SCHEME 11 CONT'D.TFA/CH₂Cl₂


- 55 -

SCHEME 12



- 56 -

SCHEME 13



- 57 -

SCHEME 13 CONT.D

5


10

15

20

25


30



- 58 -


SCHEME 14

5




benzylchloroformate, THF,
N(i-Pr)₂Et, -15°C


10




PPh₃/imidazole/I₂

15




NaN(TMS)₂, DMF, HN 

20




LDA, THF, -78°C
then allyl bromide

25



CCl₄, CH₃CN, H₂O
RuCl₃, NaIO₄

30




SCHEME 14 CONT'D.




- 60 -

SCHEME 15

5


see, Chem Ber. 76, 1019 (1943)

10




a) SOCl_2 , CH_3OH
b) benzyl chloroformate, DMF,
 $\text{N}(\text{i-Pr})_2\text{Et}$

15



20


LDA, THF, -78°C
then allyl bromide









25

trifluoroacetic acid, anisole,
 CH_2Cl_2 0°C

30



- 61 -


SCHEME 15 CONT'D

30


- 62 -

SCHEME 15 CONT'D


5





10



15



20



25

30

- 63 -

Preparation of 3-(Indol-3-yl)propanol-tert-butyl-
dimethylsilyl ether (2)

To a stirring solution of 3-indolepropanol 1
(15 g, 86 mmol), DMF (200 mL), and imidazole (12.8 g,
5 0.19 mol) at 0°C was added tert-butyldimethylsilyl
chloride (14.2 g, 95 mmol) followed by removal of the
cooling bath. After 20 hours the reaction mixture
was diluted with ether and then washed with H₂O (2
times) and brine, dried (MgSO₄), and concentrated to
10 yield the silyl ether 2 (29 g) as an amber oil.
TLC Rf= 0.54 (20% ethyl acetate/hexanes);
¹H NMR (CDCl₃) δ 8.07 (bs, 1H), 7.77 (d, J=7Hz, 1H),
7.49 (d, J=7Hz, 1H), 7.33 (t, J=7Hz, 1H), 7.26 (t,
J=7Hz, 1H), 7.12 (s, 1H), 3.84 (t, J=6Hz, 2H), 2.95
15 (t, J=7Hz, 2H), 2.08 (m, 2H), 1.08 (s, 9H), 0.25 (s,
3H), 0.22 (s, 3H).

Preparation of N-Acetyl-3-(indol-3-yl)propanol-tert-
butyldimethylsilyl ether (3)

20 A solution of the indole 2 (29 g, 86 mmol),
CH₂Cl₂ (450 mL), 1,8-diazobicyclo[5.4.0]undec-7-
ene (38 mL, 0.26 mol), 4-dimethylaminopyridine (1.0
g, 8.5 mmol), and acetic anhydride (32 mL, 0.34 mol)
25 was stirred for 1 week at ambient temperature. The
reaction mixture was concentrated and then diluted
with ether. The ether was then washed with H₂O, 5%
KHSO₄ and brine, dried (MgSO₄), and concentrated.
Flash chromatography (silica, 5% ethyl
acetate/hexanes) gave the acylated product 3 (27 g)
30 as a yellow oil.
TLC Rf= 0.56 (20% ethyl acetate/hexanes).

- 64 -

Preparation of N-Acetyl-3-(indol-3-yl)propanol (4)

To a stirred solution of the silyl ether 3 (27 g, 81 mmol) in THF (270 mL) at ambient temperature was added a premixed solution of n-Bu₄NF (1M in THF: 244 mL, 0.24 mol) and AcOH (14 mL, 0.24 mmol) (1:1). After 20 hours the reaction mixture was diluted with ether and then washed with H₂O (2 times) and brine, dried (MgSO₄), and concentrated to give the alcohol 4 (19 g) as a yellow crystalline solid.

TLC R_f = 0.35 (60% ethyl acetate/hexanes);
¹H NMR (CDCl₃) δ 8.42 (m, 1H), 7.55 (d, J=7Hz, 1H), 7.36 (t, J=7Hz, 1H), 7.29 (t, J=7Hz, 1H), 7.27 (7d, J=7Hz, 1H), 7.22 (s, 1H), 3.76 (t, J=7Hz, 2H), 2.82 (t, J=7Hz, 2H) 2.61 (s, 3H), 2.00 (m, 2H).

Preparation of 5-(N-Acetyl-indol-3-yl)pent-2-enoic acid ethyl ester (5)

To a stirring solution of oxalyl chloride (11.4 mL, 0.13 mol) in CH₂Cl₂ (440 mL) at -78°C was added dry DMSO (12.4 mL, 0.17 mol) dropwise. After 5 minutes, gas evolution ceased and the alcohol 4 (19 g, 87 mmol) in CH₂Cl₂ (40 mL) was added. After 30 minutes, NEt₃ (73 mL, 0.52 mol) was added to effect a thick slurry. The cooling bath was removed and the reaction stirred for an additional 15 minutes before adding (carbethoxymethylene)triphenyl phosphorane (33.5 g, 96 mmol). After 2.0 hours, the reaction mixture was diluted with ether and then washed with H₂O (2 times), 5% KHSO₄ and brine, dried (MgSO₄), and concentrated. Flash chromatography (20% ethyl acetate/hexanes) gave the olefin 5 (14 g) as a white solid.

- 65 -

TLC Rf= 0.54 (60% ethyl acetate/hexanes);

¹H NMR (CDCl₃) 8.42 (bd, 1H), 7.50 (d, J=7Hz, 1H),
7.34 (t, J=7Hz, 1H), 7.28 (t, J=7Hz, 1H), 7.19 (bs,
1H), 7.03 (dt, J=18 and 7Hz, 1H), 5.88 (d, J=18Hz,
1H), 4.19 (q, J=7Hz, 2H), 2.87 (t, J=7Hz, 2H), 2.63
(m, 2H), 2.61 (s, 3H), 1.28 (t, J=7Hz, 3H).

Preparation of N-(R)- α -Methylbenzyl-3(R)-[2-(indol-
3-yl)ethyl] β -alanine ethyl ester (6a) and N-(R)- α -
Methylbenzyl-3(S)-[2-(indol-3-yl)ethyl] β -alanine
ethyl ester (6b)

A mixture of olefin 5 (2.77 g, 9.7 mmol) and
R-(+)- α -methylbenzylamine (5.03 mL, 39 mmol) was
heated under a cold finger at 110°C for 40 hours.
The cooled reaction mixture was applied directly to a
flash chromatography column (silica, 40:2:1,
hexanes:ethyl acetate: 2-propanol). The (R,R) isomer
6a eluted first (1.19 g) as a viscous yellow oil
which solidified on standing. Recrystallization from
hexanes/ethyl acetate provided crystalline material.
The (R,S) isomer 6b eluted next (1.55 g) as a viscous
yellow oil containing ca 10% of the (R,R) isomer.

6a: Rf=0.52 (60% EtOAc/hexanes);
¹H NMR (400 MHz, CDCl₃) δ 7.84 (br s, 1H), 7.52 (dd,
J=7.9, 0.7 Hz, 1H), 7.20-7.35 (m, 6H), 7.16 (tm,
J=7.1, 1.3 Hz, 1H), 7.08 (tm, J=7.3, 1.1 Hz, 1H),
6.70 (br d, J=2.4 Hz, 1H), 4.10 (q, J=7.1 Hz, 2H),
3.90 (q, J=6.6 Hz, 1H), 2.80-2.90 (m, 2H), 2.68 (ABX
dt, J=16, 7.9 Hz, 1H), 2.53 (ABX dd, J=14.5, 5.9 Hz,
1H), 2.42 (ABX dd, J=14.6, 5.3 Hz, 1H), 1.79 (q,
J=7.5 Hz, 2H), 1.33 (d, J=6.4 Hz, 3H), 1.22 (t, J=7.1
Hz, 3H).

- 66 -

6b: Rf=0.42 (60% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.95 (br s, 1H), 7.57 (dd, J=7.5, 0.7 Hz, 1H), 7.34 (dm, J= 8.1, 0.7 Hz, 1H), 7.17-7.30 (m), 7.11 (tm, J=7.9, 0.9 Hz, 1H), 6.89 (br d, J=2.2 Hz, 1H), 4.02-4.15 (ABX m, 2H), 3.89 (q, J=6.6 Hz, 1H), 2.95 (m, 1H), 2.82 (ABX ddd, J=15, 9.7, 5.9 Hz, 1H), 2.69 (ABX ddd, J=15, 9.7, 6.0 Hz, 1H), 2.47 (ABX dd, J=15.0, 5.1 Hz, 1H), 2.40 (ABX dd, J=15.0, 7.7 Hz, 1H), 1.96 (m, 1H), 1.83 (m, 1H), 1.30 (d, J=6.6 Hz, 3H), 1.21 (td, J=7.1, 0.7 Hz, 3H).

Preparation of 3(R)-[2-(indol-3-yl)ethyl]β-alanine ethyl ester (7a)

Amine 6a (996 mg, 2.74 mmol) was dissolved in 10 mL EtOH. After addition of Pearlman's catalyst (20% Pd(OH)₂/C, 128 mg) the flask was charged with hydrogen and maintained at balloon pressure. After 16 hours an additional portion of catalyst was added (122 mg) along with fresh H₂. Four hours later the sample was filtered through celite and concentrated to provide amine 7a (707 mg, 99%, ca 95% pure).: Rf=0.22 (10:1, NH₃ satd. CHCl₃:EtOAc); ¹H NMR (400 MHz, CDCl₃) δ 8.01 (br s, 1H), 7.60 (dt, J=8.9, 0.4 Hz, 1H), 7.35 (dt, J=8.1, 0.9 Hz, 1H), 7.19 (td, J=7.1, 1.3 Hz, 1H), 7.11 (td, J=7.1, 1.2 Hz, 1H), 6.99 (br d, J=2.2 Hz, 1H), 4.15 (q, J=7.1 Hz, 2H), 3.72 (q, J=7.0 Hz, 1H), 3.29 (m, 1H), 2.92-2.78 (m, 2H), 2.53 (ABX dd, J=15.6, 4.0 Hz, 1H), 2.33 (ABX dd, J=15.6, 8.8 Hz, 1H), 1.92-1.73 (m, 2H), 1.25 (q, J=7.1 Hz, 3H).

- 67 -

Preparation of N-BOC-4-piperidineethanol (9).

To a stirred solution of 4-piperidineethanol **8** (18.7 g, 0.14 mol) and DMF (200mL) at 0°C was added N-tert-butoxycarbonyl anhydride (31 g, 0.14 mol).

5 After 1 hr the cooling bath was removed and the reaction mixture stirred for 20 hr. The reaction mixture was diluted with ether and then washed with water (2x) and brine, dried (MgSO₄), and concentrated to furnish **9** (26 g, 62%) as a colorless oil.

10 TLC Rf = 0.25 (40% ethyl acetate/hexanes);

¹H NMR (300 MHz, CDCl₃) δ 4.09 (bs, 2H), 3.72 (t, J= 7 Hz, 2H), 2.70 (m, 2H), 1.75-1.10 (m, 7H), 1.46 (s, 9H).

15 Preparation of N-BOC-4-piperidine ethyl iodide (10).

To a stirring solution of **9** (18.0 g, 77 mmol), triphenylphosphine (22.2 g, 85 mmol), imidazole (7.9 g, 115 mmol), and benzene (800 mL) at ambient temperature was added iodine (22.0 g, 85

20 mmol). After 5 min the heterogeneous reaction mixture was filtered and the filtrate concentrated.

Flash chromatography (silica gel, 10% ethyl acetate/hexanes) gave **10** (20 g, 59%) as an oil.

TLC Rf = 0.95 (50% ethyl acetate/hexanes);

25 ¹H NMR (300 MHz, CDCl₃) δ 4.11 (m, 2H), 3.24 (t, J= 6 Hz, 2H), 2.72 (m, 2H), 1.82 (dt, J = 7, 7 Hz, 2H), 1.75, -1.55 (m, 5H), 1.48 (s, 9H), 1.12 (m, 2H).

30

- 68 -

Preparation of N-BOC-4-piperidine ethyl azide (11).

A solution of 10 (5.0 g, 14.7 mmol), DMSO (75 mL), and NaN₃ (1.9 g, 29.4 mmol) was heated at 70° C for 2 hr. The cooled reaction mixture was
5 diluted with ethyl acetate and then washed with water (2x) and brine, dried (MgSO₄), and concentrated to afford 11 (3.6 g, 96%) as a colorless oil.
TLC Rf = 0.75 (30% ethyl acetate/hexanes);
1H NMR (300 MHz, CDCl₃) δ 4.11 (m, 2H), 3.36 (t, J= 7
10 Hz, 2H), 2.73 (m, 2H), 1.70 (m, 3H), 1.49 (s, 9H), 1.15 (m, 2H).

Preparation of N-BOC-4 piperidine ethyl amine (12).

A mixture of 11 (1.1 g, 4.3 mmol), 10 % Pd/C
15 (0.16g), and ethanol was stirred under a hydrogen atmosphere (1 atm) for 1.5 hr. The reaction mixture was then filtered through a celite pad and the filtrate concentrated to give crude 12 (1.0 g) as an oil.
20 TLC Rf = 0.18 (9:1:1 CH₂CH₂/CH₃OH/HOAc);
1H NMR (300 MHz, CDCl₃) δ 4.10 (m, 2H), 2.78 (t, J= 7 Hz, 2H), 2.70 (m, 2H), 1.80 (m, 2H), 1.67 (m, 2H), 1.52 (m, 1H), 1.47 (s, 9H), 1.17 (m, 2H).

25 Preparation of 1-[2-(N-Boc-piperidin-4-yl)ethyl]-3-propen-2-yl-(2-imidazolidinone) (14)

To a stirred solution of 13 (1.5 g, 17 mmol) in DMF (75 mL) at ambient temperature was added LiN-(TMS)₂ (1M in hexanes, 17 mL) to effect a precipi-
30 tate. Allyl bromide (1.6 mL, 19 mmol) was then added to the reaction mixture. After 15 min the

- 69 -

homogeneous mixture was treated again with $\text{LiN}(\text{TMS})_2$ (14 mL) followed by the iodide **10** (5.9 g, 17 mmol) after 5 min. The reaction was stirred for 20 hr then diluted with ether. The ether portion was washed
5 with water (2x), 5% KHSO_4 and brine, dried (Mg SO_4), and concentrated. Flash chromatography (40% ethyl acetate/hexanes) gave **14** (0.8 g, 15%) as a colorless oil.

TLC Rf = 0.46 (70% ethyl acetate/hexanes);
10 ^1H NMR (300 MHz, CDCl_3) δ 5.80 (m, 1H), 5.23 (m, 2H), 4.10 (m, 2H), 3.82 (m, 2H), 3.30 (m, 6H), 2.72 (m, 2H), 1.70 (m, 3H), 1.50 (m, 2H), 1.46 (s, 9H), 1.15 (m, 2H).

15 Preparation of 1-[2-(N-Boc-piperidine-4-yl)ethyl]-3-acetic acid-(2-imidazolidinone) (15)

To a vigorously stirred solution of **14** (450 mg, 1.4 mmol), CCl_4 , acetonitrile, and water at ambient temperature was added RuCl_3 (12 mg, 4.4 mol%)
20 and excess NaIO_4 . After 60 hr the reaction was filtered through a celite pad washing with ethyl acetate. The filtrate was extracted with sat NaHCO_3 followed by acidifying the aqueous phase to pH 3 with 5% KHSO_4 . The acidic aqueous phase was then
25 extracted with ethyl acetate (2x) and the organic portion was dried (Mg SO_4) and concentrated. Flash chromatography (silica gel, 9:0.2:0.2 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{HOAc}$) gave **15** (60 mg, 12%) as a colorless oil.

30 TLC Rf = 0.29 (9.5:0.5:0.5 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{HOAc}$);
 ^1H NMR (300 MHz, CDCl_3) δ 4.05 (m, 2H), 3.90 (m, 2H), 3.45 (m, 2H), 3.40 (m, 2H), 3.24 (m, 2H), 2.69 (m, 2H), 1.72 (m, 2H), 1.46 (m, 3H), 1.46 (s, 9H), 1.15 (m, 2H).

- 70 -

Preparation of [1-[2-(N-Boc-piperidin-4-yl)ethyl]-(2-imidazolidinone)-3]-acetyl-3(R)-[2-(indol-3-yl)-ethyl]
 β -alanine ethyl ester (16)

- 5 A stirred mixture of **15** (60 mg, 0.17 mmol),
7a (66 mg, 0.25 mmol), HOBT (30 mg, 0.22 mmol),
triethylamine (31 μ L, 0.22 mmol), and DMF (1.1 mL) at
0°C was treated with EDC (42 mg, 0.22 mmol) followed
10 by removal of the cooling bath. After 20 hr the
reaction was diluted with ethyl acetate and then
washed with water, 5% KHSO₄, and brine, dried
(MgSO₄), and concentrated. Flash chromatography
(silica gel, ethyl acetate) gave **16** (35mg, 35%) as a
colorless oil.
15 TLC Rf = 0.20 (ethyl acetate);
¹H NMR (300 MHz, CDCl₃) δ 8.07 (bs, 1H), 7.57 (d, J =
8 Hz, 1H), 7.37 (d, J = 8 Hz, 1H), 7.18 (t, J = 8 Hz,
1H), 7.11 (t, J = 8 Hz, 1H), 7.05 (bs, 1H), 6.89 (d,
J = 9 Hz, 1H), 4.37 (m, 1H), 4.13 (q, J = 7 Hz, 2H),
20 4.07 (m, 2H), 3.83 (dd, J = 18 Hz, 2H), 3.43 - 3.20
(m, 6H), 2.80 (m, 2H), 2.56 (d, J = 5 Hz, 2H), 2.00 -
1.05 (m, 9H), 1.47 (s, 9H), 1.25 (t, J = 7 Hz, 3H).

25 Preparation of [1-[2-(N-Boc-piperidin-4-yl)ethyl]-(2-imidazolidinone)-3]-acetyl-3(R)-[2-(indol-3-yl)ethyl]-
 β -alanine (17)

- A mixture of **16** (30 mg, 50 μ mol), 1N, NaOH
(0.2 mL) and ethanol was stirred at ambient tempera-
ture for 1 hr. The reaction mixture was then diluted
30 with ethyl acetate and 5% KHSO₄ and the organic
portion washed with water and brine followed by
drying (MgSO₄) and concentration to furnish **17** (30
mg, 100%) as a colorless oil.
TLC Rf = 0.74 (9:1:1 CH₂Cl₂/CH₃OH/HOAc).

- 71 -

Preparation of [1-[2-piperidin-4-yl)ethyl]-(2-im
idazolidinone)-3]-acetyl-3(R)-[2-(indol-3-yl)ethyl]
 β -alanine (18)

5 To a stirring solution of 17 (30 mg, 50
umol), dichloromethane (300 uL), and anisole (15 uL,
100 umol) at - 15°C was added TFA (0.3 mL). After 20
min the reaction mixture was concentrated and the
residual TFA removed azeotropically with toluene.
10 Flash chromatography (silica gel, 10:0.8:0.8 methanol/
NH₄)/water) gave 18 (15 mg, 66%) as a white solid.
TLC Rf = 0.16 (10:1:1 methanol/NH₄OH/water);
1H NMR (300 MHz, CD₃OD) δ 7.44 (d, J = Hz, 1H), 7.20
(d, J = 8 Hz, 1H), 6.95 (t, J = 8 Hz, 1H), 6.94 (s,
15 1H), 6.88 (t, J = 8 Hz, 1H), 4.17 (m, 1H), 3.71 (s,
2H), 3.40)3.10 (m, 8H), 2.86 (m, 2H), 2.70 (t, J = 6
Hz, 2H), 2.32 (m, 2H), 1.90 (m, 4H), 1.55 (m, 1H),
1.43 (m, 2H), 1.28 (m, 2H).

20 Preparation of 1-[2-(N-Boc-piperidin-4-yl)ethyl]-(2-
pyrrolidinone) (19)

 To a stirred solution of 12 (2.7 g, 11.8
mmol) acetonitrile (60 mL), and diisopropyl
ethylamine (4.1 mL 23.6 mmol) at 0°C was added
25 4-chlorobutyl chloride (2.6 mL, 23.6 mmol) followed
by removal of the cooling bath. After 5 hr the
reaction mixture was diluted with ethyl acetate and
then washed with water (2x) and brine, dried (MgSO₄),
and concentrated. The crude amide was dissolved in
30 DMF (60 mL) cooled to 0°C then treated with NaN(TMS)₂
(1M in THF, 11.8 mL). After 5 min the reaction
mixture was diluted with ethyl acetate and then

- 72 -

washed with water and brine, dried (MgSO_4), and concentrated. Flash chromatography (silica gel, 70% ethyl acetate/hexanes); gave 19 (0.4 g, 12%) as a colorless oil.

5 TLC Rf = 0.27 (70% ethyl acetate/hexanes);

^1H NMR (300 MHz, CDCl_3) δ 4.10 (m, 2H), 3.39 (t, J = 7 Hz, 2H), 3.34 (t, J = 7 Hz, 2H), 2.70 (m, 2H), 2.40 (m, 2H), 2.05 (m, 2H), 1.72 (m, 2H), 1.46 (m, 3H), 1.45 (s, 9H), 1.13 (m, 2H).

10

Preparation of 1-[2-(N-Boc-piperidin-4-yl)ethyl]-3-propen-2-yl-(2-pyrrolidinone) (20)

To a stirred solution of 19 (325 mg, 1.1 mmol) in THF (5 mL) at -78°C was added LDA (0.5 M in THF 2.4 mL) dropwise. After 15 min allyl bromide (0.16 mL, 2.2 mmol) was added and the reaction stirred at -78°C for 1 hr followed by quenching with HOAc (0.1 mL). The reaction mixture was then diluted with ethyl acetate and then washed with water and

15

20

gave 20 (160 mg, 45%) as an oil.

TLC Rf = 0.23 (50% ethyl acetate/hexanes);

^1H NMR (300 MHz, CDCl_3) δ 5.80 (m, 1H), 5.10 (m, 2H), 4.10 (m, 2H), 3.32 (m, 4H), 2.70 (m, 2H), 2.56 (m, 2H), 2.20 (m, 2H), 1.73 (m, 3H), 1.48 (s, 9H), 1.13 (m, 2H).

25

30

- 73 -

Preparation of 1-[2-(N-Boc-piperidin-4-yl)ethyl]-3-acetic acid-2-pyrrolidinone (21)

Utilizing the procedure for converting 14 to 15, 20 (130 mg, 0.4 mmol) gave 21 (80 mg, 48%) as an oil after flash chromatography (silica gel, 9:0.2:0.2 CH₂Cl₂/CH₃OH/HOAc).

TLC Rf=0.25 (9:0.2:0.2 CH₂Cl₂/CH₃OH/HOAc);

¹H NMR (300 MHz, CDCl₃) δ 4.05 (m, 2H), 3.40 (m, 4H), 2.96 (m, 1H), 2.83 (m, 1H), 2.70 (m, 2H), 2.55 (m, 1H), 2.40 (m, 1H), 1.90-1.10 (m, 7H), 1.48 (s, 9H).

Preparation of [1-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-3]acetyl-[2-(indol-3-yl)-ethyl]β-alanine ethyl ester (22)

Utilizing the procedure for converting 15 to 16, 21 (120 mg, 0.35 mmol) gave 22 (90 mg, 48%) after flash chromatography (silica gel, ethyl acetate).

TLC Rf=0.40 (ethyl acetate);

¹H NMR (400 MHz, CDCl₃) δ 8.09 (bd, 1H), 7.58 (d, J=8 Hz, 1H), 7.36 (d, J=8 Hz, 1H), 7.17 (t, J=8 Hz, 1H), 7.10 (t, J=8 Hz, 1H), 7.07 (bs, 1H), 4.39 (m, 1H), 4.12 (q, J=7 Hz, 2H), 4.05 (m, 2H), 3.30 (m, 4H), 2.90-2.25 (m, 8H), 2.00-1.00 (m, 8H), 1.48 (s, 9H), 1.23 (t, J=7 Hz, 3H).

Preparation of [1-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-3]acetyl-[2-(indol-3-yl)-ethyl]β-alanine (23)

Utilizing the procedure for converting 16 to 17, 22 (80 mg, 0.14 mmol) gave 23 (80 mg) after work-up, which was used directly for the next reaction.

TLC Rf=0.50 (9:1:1 CH₂Cl₂/CH₃OH/HOAc).

- 74 -

Preparation of [1-[2-(piperidin-4-yl)ethyl]-2-pyrroli-
dinone-3]acetyl-[2-(indol-3-yl)-ethyl] β -alanine-(24)

5 Utilizing the procedure for converting 17 to
18, 23 (80 mg, 0.14 mmol) gave 24 (15 mg, 23%) after
flash chromatography (silica gel, 10:0.65:0.65
methanol/ NH_4OH /water).

TLC R_f =0.53 (10:1:1 methanol/ NH_4OH /water);

10 ^1H NMR (300 MHz, CD_3OD) δ 7.47 (t, J =7 Hz, 1H), 7.25
(d, J =7 Hz, 1H), 6.99 (m, 2H), 6.88 (t, J =7 Hz, 1H),
4.19 (m, 1H), 3.49 (m, 0.5 H), 3.40 (m, 0.5H),
3.34-2.95 (m, 6H), 2.90-2.60 (m, 4H), 2.48 (m, 1H),
2.40-2.20 (m, 4H), 2.13 (m, 1H), 2.00-1.05 (m, 11H).

15 Preparation of 5-chloro-valeroyl-amino-2-propene (26)

To a stirred mixture of allyl amine 25 (2.0
g, 27 mmol), NMM (8.9 mL, 81 mmol), and acetonitrile
(140 mL), at ambient temperature was added 4-chloro-
20 butyryl chloride (3.4 mL, 27 mmol). After 20 hours
the reaction mixture was concentrated. The residue
was dissolved in ethyl acetate and then washed with
water, 5% KHSO_4 and brine, dried (MgSO_4), and
concentrated to give 26 (4.1 g, 87%) as a yellow oil.
TLC R_f =0.17 (40% ethyl acetate/hexanes).

25

Preparation of 1-(propen-2-yl)-2-piperidone (27)

To a stirred solution of 26 (2.0 g, 11 mmol)
in THF (110 mL) at -78°C was added $\text{NaN}(\text{TMS})_2$ (1.0 M
in THF, 11 mL) in a stream followed by removal of the
30 cooling bath. After 1.5 hours the reaction mixture
was diluted with ethyl acetate and then washed with
water, 5% KHSO_4 and brine, dried (MgSO_4), and
concentrated. Flash chromatography (silica g 1, 60%

- 75 -

ethyl acetate/hexanes) gave 27 (1.1 g, 72%) as an oil.
TLC Rf=0.15 (60% ethyl acetate/hexanes);
¹H NMR (300 MHz, CDCl₃) δ 5.78 (m, 1H), 5.15, 4.00
(d, J=7 Hz, 2H), 3.24 (m, 2H), 2.41 (m, 2H), 2.07 (m,
5 2H), 1.80 (m, 4H).

Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-1-acetic acid-2-piperidone (28)

To a stirred solution of 27 (1.0 g, 7.2
10 mmol) and THF (70 mL) at -78°C was added LDA (0.5 M
in THF, 15.8 mL) dropwise. After 15 minutes iodide
10 (2.7 g, 7.9 mmol) in THF (5 mL) was added followed
by slow warming to -30°C over a 1 hour period. The
reaction was quenched with acetic acid (0.2 mL) then
15 concentrated. Flash chromatography (silica gel, 40%
ethyl acetate/hexanes) gave 28 (1.5 g, 59%) as an oil.
TLC Rf=0.58 (ethyl acetate);
¹H NMR (300 MHz, CDCl₃) δ 5.77 (m, 1H), 5.15 (m, 1H),
4.06 (m, 2H), 4.00 (m, 2H), 3.23 (m, 2H), 2.59 (m,
20 2H), 2.19 (m, 1H), 2.05-1.25 (m, 11H), 1.48 (s, 9H),
1.10 (m, 2H).

Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-3-acetic acid-2-piperidone (29)

A vigorously stirred mixture of 28 (0.84 g,
25 2.4 mmol), CCl₄ (5 mL), acetonitrile (5 mL), NaIO₄
(2.1 g, 9.8 mmol), and water (7.5 mL) at ambient
temperature was treated with RuCl₃ (50 mg, 0.24
mmol). After 20 hours additional RuCl₃ ((50 mg) was
30 added. After 4 hours the reaction mixture was
diluted with ethyl acetate and half sat NaHCO₃.
After shaking and separation the aqueous portion was

- 76 -

acidified with 5% KHSO₄, and extracted with ethyl acetate. The organic extracts were washed with brine, dried (MgSO₄), and concentrated. Flash chromatography (silica gel, 9:0.2:0.2 CH₂Cl₂/methanol/HOAc) gave 29 (280 mg, 30%) as an oil.
TLC Rf=0.36 (9:0.5:0.5 CH₂Cl₂/methanol/HOAc).

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-imidazolidinone-1]acetyl-[3(R)-[2-(indol-3-yl)ethyl]-β-alanine ethyl ester (30)

Utilizing the procedure for converting 15 to 16, 29 (280 mg, 0.76 mmol) gave 30 (300 mg, 64%) as an oil after flash chromatography (silica gel, 85% ethyl acetate/hexanes).

TLC Rf=0.18 (85% ethyl acetate/hexanes);
¹H NMR (300 MHz, CDCl₃) δ 8.14 (m, 1H), 7.60 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.20 (t, J=8 Hz, 1H), 7.13 (t, J=8 Hz, 1H), 7.05 (bs, 1H), 6.90 (d, J=9 Hz, 1H), 4.35 (m, 1H), 4.11 (q, J=7 Hz, 2H), 4.05 (m, 2H), 3.98 (s, 2H), 3.40 (m, 2H), 2.90-2.50 (m, 6H), 2.33 (m, 1H), 2.00-1.00 (m, 15H), 1.48 (s, 9H), 1.27 (9t, J=7 Hz, 3H).

25

30

- 77 -

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-[3(R)-[2-indol-3-yl)ethyl]β-alanine (31)

5 Utilizing the procedure for converting 16 to 17, 30 (160 mg, 0.26 mmol) gave 31 (140 mg, 92%) as a white solid after work-up.
TLC Rf=0.59 (9:1:1 CH₂Cl₂/methanol/HOAc).

10 Preparation of [3-[2-(piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-[3(R)-[2-indol-3-yl)ethyl]β-alanine (32)

Utilizing the procedure for converting 17 to 18, 31 (140 mg, 0.24 mmol) gave 32 (55 mg, 47%) as a white solid after flash chromatography (silica gel, 15 10:0.4:0.4 methanol/NH₄OH/water).
TLC Rf=0.46 (10:1:1 methanol/NH₄OH/water);
1H NMR (300 MHz, CD₃OD) δ 7.54 (d, J=8 Hz, 1H), 7.30 (d, J=8 Hz, 1H), 7.03 (t, J=8 Hz, 1H), 7.02 (bs, 1H), 6.97 (m, 1H), 4.28 (m, 1H), 4.20 (d, J=16 Hz, 0.5H), 20 4.12 (d, J=16 Hz, 0.5H), 3.80 (d, J=16 Hz, 0.5H), 3.75 (d, J=16 Hz, 0.5H), 3.50-3.15 (m, 4H), 2.80 (m, 4h), 2.50-2.30 (m, 3H), 2.00-1.20 (m, 15H).

25 Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone (36a)

To the benzyl amide 35a (0.8 g, 2.2 mmol) in THF (20 mL) at -78°C was added freshly prepared lithium di-tert-butylbiphenyl (0.5 M in THF, 10.8 mL)

30

- 78 -

in 2 portions. After 1 hour the reaction mixture was quenched with HOAc (0.1 mL) followed by concentration. Flash chromatography (5% methanol/ethyl acetate) gave 36a (470 mg, 72%) as a white solid.

TLC Rf=0.27 (10% methanol/ethyl acetate);

^1H NMR (300 MHz, CDCl_3) δ 6.03 (m, 1H), 4.10 (m, 2H), 3.35 (m, 2H), 2.70 (m, 2H), 2.33 (m, 2H), 1.92 (m, 1H), 1.80 (m, 1H), 1.70 (m, 2H), 1.50-1.30 (m, 4H), 1.48 (s, 9H), 1.12 (m, 2H).

Preparation of Methyl 1-acetate-3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone (37a)

To a stirred solution of 36a (340 mg, 1.1 mmol) in THF (10 mL) at -78°C was added $\text{NaN}(\text{TMS})_2$ (1.0 M in THF, 1.1 mL). After 15 minutes ethyl bromoacetate (250 μL , 2.2 mmol) was added and the reaction mixture to warm to -20°C . After 2 hours the reaction was quenched with HOAc (0.1 mL) and then concentrated. Flash chromatography (silica gel, 50% ethyl acetate/hexanes) gave 37a (380 mg, 90%) as an oil.

TLC Rf=0.66 (10% methanol/ethyl acetate);

^1H NMR (300 MHz, CDCl_3) δ 4.22 (q, $J=7$ Hz, 2H), 4.10 (m, 2H), 4.08 (s, 2H), 3.24 (m, 2H), 2.70 (m, 2H), 2.44 (m, 1H), 2.26 (m, 1H), 2.00-1.65 (m, 4H), 1.48 (s, 9H), 1.50-1.30 (m, 4H), 1.31 (t, $J=7$ Hz, 3H), 1.12 (m, 2H).

- 79 -

Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-1-acetic acid (38a)

Utilizing the procedure for converting 16 to 17, 37a (390 mg, 1.1. mmol) gave 38a (340 mg, 91%) as a white foam after work-up.

TLC Rf=0.39 (9:0.5:0.5 CH₂Cl₂/methanol/HOAc).

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-1]acetyl-[3(R)-(indol-3-yl)-ethyl]β-alanine ethyl ester (39a)

Utilizing the procedure for converting 15 to 16, 38a (310 mg, 0.92 mmol) gave 39a (460 mg, 86%) as a yellow oil after flash chromatography (silica gel, 85% ethyl acetate/hexanes).

TLC Rf=0.16 (85% ethyl acetate/hexanes);

¹H NMR (300 MHz, CDCl₃) δ 8.21 (bs, 1H), 7.58 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.20 (t, J=8 Hz, 1H), 7.13 (t, J=8 Hz, 1H), 7.05 (bs, 1H), 6.72 (d, J=10 Hz, 1H), 4.35 (m, 1H), 4.13 (q, J=7 Hz, 2H), 4.09 (m, 2H), 3.97 (d, J=15 Hz, 1H), 3.86 (d, J=15 Hz, 1H), 3.41 (m, 2H), 2.80 (m, 2H), 2.65 (m, 2H), 2.55 (dd, J=1.5 Hz, 2H), 2.45 (m, 1H), 2.24 (m, 1H), 2.00-1.20 (m, 10 H), 1.48 (s, 9H), 1.26 (t, J=7 Hz, 3H), 1.04 (m, 2H).

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl-1]-acetyl-[3(R)-[2-(indol-3-yl)ethyl]β-alanine (40a)

Utilizing the procedure for converting 16 to 17, 39a (460 mg, 0.79 mmol) gave 40a (360 mg, 86%) as a foam after work-up.

TLC Rf=0.57 (9:1:1 CH₂Cl₂/methanol/HOAc).

- 80 -

Preparation of [3-[2-(piperidin-4-yl)ethyl-1]acetyl-
[3(R)-[2-(indol-3-yl)ethyl]β-alanine (41a)

Utilizing the procedure for converting 17 to
18, 40a (360 mg, 0.65 mmol) gave 41a (180 mg, 59%) as
5 a white solid after flash chromatography (silica gel,
10:0.4:0.4 methanol/NH₄OH/water).

TLC Rf=0.21 (10:0.4:0.4 methanol/NH₄OH/water);
1H NMR (300 MHz, CD₃OD) δ 7.36 (d, J=8 Hz, 1H), 7.13
(d, J=8 Hz, 1H), 6.87 (t, J=8 Hz, 1H), 6.86 (s, 1H),
10 6.78 (t, J=8 Hz, 1H), 4.09 (m, 1H), 3.82 (d, J=16 Hz,
1H), 3.70 (d, J=16 Hz, 1H), 3.33 (m, 2H), 3.07 (m,
2H), 2.63 (m, 4H), 2.30 (m, 1H), 2.25 (m, 2H), 2.05
(m, 1H), 1.90-1.50 (m, 6H), 1.40-1.05 (m, 6H).

15 Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-
pyrrolidinone (36b)

Utilizing the procedure for converting 35a
to 36a, 35b (0.7 g, 1.7 mmol) gave 36b (260 mg, 62%)
as a white solid after flash chromatography (silica
20 gel, 5% methanol/ethyl acetate).
TLC = Rf = 0.27 (10% methanol/ethyl acetate).

Preparation of Ethyl 3-[2-N-Boc-piperidin-4-yl)ethyl]-
2-pyrrolidinone-1-acetate (37b)

25 Utilizing the procedure for converting 36a
to 37a, 36b (260 mg, 0.88 mmol) gave 37b (300 mg,
89%) as an oil after flash chromatography (silica
gel, 50% ethyl acetate/hexanes).
TLC Rf = 0.66 (10% methanol/ethyl acetate).

30

- 81 -

Preparation of 3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-1-acetic acid (38b)

Utilizing the procedure for converting 16 to 17, 37b (300 mg, 0.78 mmol) gave 38b (260 mg, 98%) as a crystalline solid.

TLC Rf = 0.38 (9:0.5:0.5 CH₂Cl₂/methanol/HOAc).

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-1]acetyl-[3(R)-[2-(indol-3-yl)-ethyl]β-alanine ethyl ester (39b)

Utilizing the procedure for converting 15 to 16, 38b (260 mg, 0.73 mmol) gave 39b (360 mg, 83%) as an oil after flash chromatography (silica gel, 85% ethyl acetate/hexanes).

TLC Rf = 0.16 (85% methanol/ethyl acetate);

¹H NMR (300 MHz, CDCl₃) δ 8.29 (bs, 1H), 7.57 (d, J = 8 Hz, 1H), 7.38 (d, J = 8 Hz, 1H), 7.19 (t, J = 8 Hz, 1H), 7.12 (t, J = 8 Hz, 1H), 7.04 (d, J = 1 Hz, 1H), 6.67 (d, J = 10 Hz, 1H), 4.33 (m, 1H), 4.13 (q, J = 7 Hz, 2H), 4.07 (m, 2H), 3.99 (d, J = 16 Hz, 1H), 3.82 (d, J = 16 Hz, 1H), 3.40 (m, 2H), 2.80 (m, 2H), 2.68 (m, 3H), 2.55 (dd, J = 5, 2 Hz, 2H), 2.43 (m, 1H), 2.22 (m, 1H), 2.00 - 1.00 (m, 11H), 1.47 (s, 9H), 1.28 (t, J=7Hz, 3H).

Preparation of [3-[2-(N-Boc-piperidin-4-yl)ethyl]-2-pyrrolidinone-1]acetyl-[3(R)-[2-indol-3-yl)-ethyl]β-alanine (40b)


Utilizing the procedure for converting 16 to 17, 39b (280 mg, 0.47 mmol) gave 40b (250 mg, 94%) as a white solid after flash chromatography (silica gel, 9:1:1 CH₂Cl₂/methanol/HOAc).

TLC Rf = 0.21 (9:1:1 CH₂Cl₂/methanol/HOAc).

- 82 -

Preparation of [3-[2-(N-piperidin-4-yl)ethyl]-2-pyrrolidinone-1]acetyl-[3 (R)-[2-(indol-3-yl)-ethyl]β-alanine (41b)

Utilizing the procedure for converting **17** to **18**, **40b** (250 mg, 0.44 mmol) gave **41b** (100 mg, 49%) as a white solid after flash chromatography (silica gel, 10:0.4:0.4 methanol/NH₄OH/water).
 TLC R_f = 0.46 (10:0.4:0.4 methanol/NH₄OH/water);
¹H NMR (300 MHz, CD₃OD) δ 7.52 (d, J = 8 Hz, 1H), 7.29 (d, J = 8 Hz, 1H), 7.03 (t, J = 8 Hz, 1H), 7.02 (s, 1H), 6.95 (t, J = 8 Hz, 1H), 4.27 (m, 1H), 4.05 (d, J = 16 Hz, 1H), 3.81 (d, J = 16 Hz, 1H), 3.42 (m, 2H), 3.26 (m, 2H), 2.90-2.70 (m, 4H), 2.49 (m, 1H), 2.40 (d, J = 6 Hz, 2H), 2.22 (m, 1H), 2.05 - 1.70 (m, 5H), 1.60 - 1.25 (m, 5H).



Ethyl 4-(N-BOC-piperidin-4-yl)crotonate(42)

To a stirred solution of oxalyl chloride (0.43 mL, 5.0 mmol) in CH₂Cl₂ (20mL) at -78°C was added DMSO (0.52ml, 7.0 mmol) dropwise. After gas evolution subsided (~5 minutes) the alcohol **9** (0.8 g, 3.5 mmol) in CH₂Cl₂ (20 mL) was added in a stream. After 20 minutes triethylamine (1.7 mL, 12 mmol) was added dropwise and then the cooling bath removed.

- 83 -

After 20 minutes carbethoxymethylenetriphenylphosphorane (1.4g, 4.0 mmol) was added in one portion. After 2.0 hours the reaction mixture was diluted with petroleum ether and then washed sequentially with H₂O, 5% KHSO₄, and brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 15% ethyl acetate/hexanes) gave the ester 42 as a colorless oil.

TLC Rf = 0.79 (50% ethyl acetate/hexanes);
¹H NMR (300 MHz, CDCl₃) δ 6.91 (dt, J = 16 and 7 Hz, 1H), 5.81 (bd, J = 17 Hz, 1H), 4.18 (q, J = 7 Hz, 2H), 4.08 (m, 2H), 2.67 (m, 2H), 2.14 (t, J = 7 Hz, 2H), 1.70-1.05 (m, 5H), 1.44 (s, 9H), 1.28 (t, J = 7H, 3H).

Preparation of Ethyl 4-(N-BOC-piperidin-4-yl)-butyrate (43)

The olefin 42 (26g, 87mmol) in ethyl acetate (500 mL) was hydrogenated, at ambient temperature, under a hydrogen atmosphere (1 atm) in the presence of 10% Pd/C (5.0g) overnight. The reaction mixture was then purged with argon and filtered through a celite pad. Concentration of the filtrate followed by flash chromatography (silica, 10% ethyl acetate/hexanes) gave the ester 43 as a crystalline solid.

TLC Rf = 0.42 (20% ethyl acetate/hexanes); ¹H NMR (300 MHz, CDCl₃) δ 4.16 (q, J = 7 Hz, 2H), 4.10 (m, 2H), 2.69 (m, 2H), 2.31 (t, J = 7 Hz, 2H), 1.68 (m, 4H), 1.38 (s, 9H), 1.40 (m, 1H), 1.11 (m, 2H).

- 84 -

Preparation of 4-(N-BOC-Piperin-4-yl)butanoic
acid (44)

5 A solution of ester 43 (19g, 63mmol),
ethanol (300 mL) and 1 N NaOH (100 mL, 100mmol) was
stirred at ambient temperature for 2.5 hours
followed by concentration. The residue was diluted
with 5% KHSO₄ and ethyl acetate and then transferred
10 to a separatory funnel. The phases were shaken then
separated and then the organic portion was washed
with brine, dried (MgSO₄), and concentrated to give
the acid 44 as a colorless oil that crystallized
upon standing.

15 mp = 80 - 81°C; TLC Rf = 0.68 (ethyl acetate); ¹H
NMR (300 MHz, CDCl₃) δ 4.10 (m, 2H), 2.71 (m, 2H),
2.38 (t, J = 7Hz, 2H), 1.70 (m, 4H), 1.60-1.30
(m, 3H), 1.48 (s, 9H), 1.12 (m, 2H).

20 Preparation of 4(S)-Benzyl-2-oxazolidinone-4-(BOC-
piperidin-4-yl) butyrate (45)

To a stirred solution of 44 (15.3g, 56mmol),
NEt₃ (9.4mL, 67mmol) and dry THF (240mL) at -78°C
was added trimethylacetyl chloride (7.6mL, 61mmol)
25 in a stream. After 10 min. the cooling bath was
removed and replaced with an icebath. After 1.0 h
the heterogeneous mixture was recooled to -78°C
followed by cannula addition of lithium
(S)-(-)-4-benzyl-2-oxazolidinone (62mmol) in dry THF
30 (150mL) AT -78°C with n-BuLi (38.8mL, 62mmol, 1.6

- 85 -

M/hexanes). After addition was complete, the reaction mixture was warmed to 0°C for 1.0 h, and then diluted with ethyl acetate and washed with H₂O, sat. NaHCO₃, 5% KHSO₄ and brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 30% ethyl acetate/hexanes) gave 45 as a colorless oil.

TLC Rf = 0.45 (30% ethyl acetate/hexanes); ¹H NMR (400 MHz, CDCl₃) 7.36-7.20 (m, 5H), 4.67 (m, 1H), 4.18 (m, 2H), 4.08 (m, 2H), 3.30 (dd, J = 13 and 3 Hz, 1H), 2.93 (m, 2H), 2.77 (dd, J = 13 and 10 Hz, 1H), 2.69 (m, 2H), 1.70 (m, 4H), 1.50-1.30 (m, 3H), 1.45 (s, 9H), 1.11 (m, 2H).

Preparation of 4(S)-Benzyl-2-oxazolidinone-4-(BOC-piperidin-4-yl)-2(R)-(2-cyanoethyl)butyrate (46)

To a stirred solution of TiCl₄ (42 mL, 42 mmol, 1M/CH₂Cl₂) and CH₂Cl₂ (250 mL) at 0°C was added titanium (IV) isopropoxide (4.2 mL, 14 mmol). After 15 min. diisopropylethylamine (11.0 mL) in CH₂Cl₂ (75 mL) was added followed by continued stirring at 0°C to the deep red solution. After 10 minutes, 45 (21.8 g, 51 mmol) in CH₂Cl₂ (75 mL) was added followed by continued stirring at 0°C for 1.0 hour. Acrylonitrile (33.4 mL, 0.50 mol) was added at 0°C to the deep red solution. After 4.0 h the reaction was quenched with sat. NH₄Cl (150 mL) at 0°C, then extracted with CH₂Cl₂ (3x250 mL). The combined organic extracts were washed with sat. NaHCO₃ and brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 25% ethyl acetate/hexanes)

- 86 -

gave crude **46** as a yellow oil. Crude **46** was chromatographed (silica, 2.5% acetone/ CH_2Cl_2) to yield **46** as an oil which was 97% pure by HPLC in addition to mixed fractions (1.6g).

5

TLC Rf = 0.35 (2.5% acetone/ CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.50-7.30 (m, 5H), 4.68 (m, 1H), 4.21 (m, 2H), 4.07 (m, 2H), 3.80 (m, 1H), 3.33 (dd, J = 13 and 4 Hz, 1H), 2.77 (dd, J = 13 and 10 Hz, 1H), 2.65 (m, 2H), 2.38 (m, 2H), 2.13 (m, 1H), 1.89 (m, 1H), 1.75 (m, 1H), 1.63 (m, 2H), 1.50 (m, 2H), 1.45 (s, 9H), 1.35 (m, 1H), 1.25 (m, 2H), 1.08 (m, 2H).

10

Preparation of 4(S)-Cyclohexylmethyl-2-oxazolidinone-4-(BOC-piperidin-4-yl)-2(R)-(2-aminopropyl) butyrate•HCl (**47**)

15

A mixture of **46** (19.2g, 40 mmol), PtO_2 (2.0g), CH_3OH (70 mL) and CHCl_3 (7.0 mL) was shaken on the Parr apparatus under a hydrogen atmosphere (60 PSI) at ambient temperature for 3.0 h. The reaction mixture was filtered through a celite pad and then concentrated to furnish the crude amine•HCl **47** as a white solid. This material was used directly in the next step.

20

25

TLC Rf = 0.50 (10:1:1 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{HOAc}$); ^1H NMR (400 MHz, CDCl_3) δ 8.28 (bs, 2H), 4.50 (m, 1H), 4.35 (m, 1H), 4.14 (m, 1H), 4.03 (m, 2H), 3.63 (m, 1H), 3.02 (m, 2H), 2.63 (m, 2H), 2.00-1.00 (m, 24H), 1.45 (s, 9H).

30

- 87 -

Preparation of 3-(R)-[N-BOC-2-(piperidin-4-yl)ethyl]-
2-piperidone (48)

The crude amine•HCl 47 (16.6 g, 31 mmol),
acetonitrile (750 mL), and NaHCO₃ (10.0 g) was
5 stirred at ambient temperature for 20 h. The
heterogeneous mixture was then treated with
di-tert-butylidicarbonate (3.0g) followed by continued
stirring for 1.0 h to reprotect minor amounts of free
piperidine that formed in the previous reaction. The
10 NaHCO₃ was removed by filtration and the filtrate
concentrated. Flash chromatography (silica, 5%
CH₃OH/ethyl acetate) gave the lactam 48 as a
colorless crystalline solid.

15 mp = 110-111°C; TLC Rf = 0.65 (20% CH₃OH/ethyl
acetate); ¹H NMR (400 MHz, CDCl₃) δ 6.31 (bs, 1H),
4.06 (m, 2H), 3.31 (m, 2H), 2.67 (m, 3H), 2.28 (m, 1H),
2.00-1.20 (m, 11H), 1.45 (s, 9H), 1.10 (m, 2H).

20 Preparation of Ethyl [3(R)-[N-BOC-2-(Piperidin-4-yl)-
ethyl]-2-piperidone-1] acetate (49)

To a stirred solution of 48 (6.7g, 22 mmol)
and dry THF (150 mL) at -78°C was added NaN(TMS)₂
(24.5 mL, 24.5 mmol, 1M/hexanes) dropwise. After 15
25 min. ethyl bromoacetate (5.2 mL, 45 mmol) was added
and then the reaction mixture warmed to 0°C for 1.0
h. The reaction was quenched with AcOH (1.0 mL) then
diluted with ethyl acetate, washed with H₂O and
brine, dried (MgSO₄), and concentrated. Flash
30 chromatography (silica, 40% ethyl acetate/hexanes)
gave the ester 49 as a yellow oil.

- 88 -

TLC Rf = 0.26 (40% ethyl acetate/hexanes); ¹H NMR (300 MHz, CDCl₃) δ 4.20 (q, J = 7 Hz, 2H), 4.17 (d, J = 18 Hz, 1H), 4.08 (m, 2H), 3.98 (d, J = 18 Hz, 1H), 3.37 (m, 2H), 2.68 (m, 2H), 2.32 (m, 1H), 2.00-1.25 (m, 11H), 1.45 (s, 9H), 1.30 (t, J = 7 Hz, 3H), 1.11 (m, 2H).

Preparation of 3-(R)-[N-BOC-2-(Piperidin-4-yl)ethyl]-2-piperidone-11 acetic acid (50)

A solution of 49 (6.0g, 15 mmol), 1N NaOH (50 mL, 50 mmol), and CH₃OH (75 mL) was stirred at ambient temperature for 1.0 h. The reaction mixture was then acidified with 5% aqueous KHSO₄ and then extracted with ethyl acetate. The organic portion was washed with brine, dried (MgSO₄), and concentrated to give the carboxylic acid 50 as a yellow oil. The oil was triturated with hexanes to give a fluffy white solid.

TLC Rf = 0.31 (9:0.5:0.5 CH₂Cl₂/CH₃OH/AcOH); ¹H NMR (400 MHz, CDCl₃) δ 4.13 (d, J = 17 Hz, 1H), 4.07 (m, 2H), 4.06 (d, J = 17 Hz, 1H), 3.39 (m, 2H), 2.33 (m, 1H), 1.95 (m, 3H), 1.81 (m, 1H), 1.70-1.25 (m, 7H), 1.45 (s, 9H), 1.08 (m, 2H).

Preparation of 3(R)-BOC-Amino-1-azobutan-2-one (52)

To a stirred solution of 51 (3.8 g, 20 mmol), 4-methylmorpholine (2.2 mL, 20 mmol), and ethyl acetate (200 mL) at -15°C was added isobutyl chloroformate (2.6 mL, 20 mmol). After 1.0h the reaction mixture was washed with H₂O and brine, dried

- 89 -

(MgSO₄), and filtered into a round bottom flask. After cooling to 0°C the mixed anhydride was treated portion-wise with an ethereal solution of diazomethane (80 mL, 40 mmol, 80.5 M solution).

5 After 2.0 h the cooling bath was removed and the excess diazomethane removed by purging the solution with argon for 30 min. Concentration gave the crude diazoketone 52 which was used directly for the next step.

10

TLC Rf = 0.37 (30% ethyl acetate/hexanes).

Preparation of Ethyl N-BOC-3(R)-Methyl β-alanine (53)

15 The crude diazoketone 52 (4.3g, ~20.0 mmol) was dissolved in ethanol (250 mL) and treated sequentially with NEt₃ (3.4 mL, 24 mmol) and silver benzoate (1.4g, 6.0 mmol) to effect vigorous gas evolution and afford a black precipitate. After 1.0 h the reaction mixture was concentrated and the
20 residue purified by flash chromatography (silica, 10% ethyl acetate/hexanes) to give the ethyl ester 53 as a colorless oil.

25 TLC Rf = 0.42 (30% ethyl acetate/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 4.96 (m, 1H), 4.19 (q, J = 7 Hz, 2H), 4.04 (m, 1H), 2.52 (dd, J = 15 and 6 Hz, 1H), 2.46 (dd, J = 15 and 6 Hz, 1H), 1.44 (s, 9H), 1.26 (t, J = 7 Hz, 3H), 1.21 (d, J = 7 Hz, 3H).

30

- 90 -

Preparation of Ethyl 3(R)-Methyl β -alanine \cdot HCl (54)

To a mechanically stirred solution of 53 (2.2g, 9.7 mmol) in ethyl acetate (180 mL) at -15°C was vigorously bubbled HCl gas for 30 min. The cooling bath (ethanol/ice) was removed and the solution purged with argon for 1.0 h to remove excess HCl. Concentration furnished the amine \cdot HCl 54 as a yellow oil.

^1H NMR (400 MHz, D_2O) δ 4.23 (q, $J = 7$ Hz, 2H), 3.78 (m, 1H), 2.79 (m, 2H), 1.38 (d, $J = 7$ Hz, 3H), 1.29 (t, $J = \text{Hz}$, 3H).

Preparation of [3(R)-[N-BOC-2-(Piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-3(R)-methyl- β -alanine ethyl ester (55)

To a stirred solution 50 (1.0 g, 2.7 mmol), 54 (0.48 g, 2.8 mmol), HOBT (0.39g, 2.8 mmol), $\text{N}(\text{i-pr})_2\text{Et}$ (1.5 mL, 8.5 mmol), and dry DMF (100 mL) at -15°C was added EDC (0.95 g, 2.8 mmol) followed by removal of the cooling bath. After 20 h the reaction mixture was diluted with ethyl acetate and then washed with H_2O , sat. NaHCO_3 , 5% aqueous KHSO_4 and brine, dried (MgSO_4), and concentrated. Flash chromatography (silica, ethyl acetate) gave 55 as a colorless oil.

TLC $R_f = 0.35$ (ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 6.82 (bd, 1H), 4.32 (m, 1H), 4.13 (q, $J = 7$ Hz, 2H), 4.10 (d, $J = 15$ Hz, 1H), 4.08 (m, 2H), 4.82

- 91 -

(d, J = 15 Hz, 1H), 3.36 (m, 2H), 2.67 (m, 2H), 2.48 (dd, J=5 and 1 Hz, 2H), 2.33 (m, 1H), 2.00-1.20 (m, 11H), 1.45 (s, 9H), 1.27 (t, J = 7 Hz, 3H), 1.21 (d, J = 7 Hz, 3H), 1.10 (m, 2H).

5

Preparation of [3(R)-[N-BOC-2-(Piperidin-4-yl)ethyl]-2-piperidone-1-lacetyl-3(R)-methyl- β -alanine (56)]

A solution of 55 (1.2 g, 2.5 mmol), 1N NaOH (10 mL, 10 mmol), and CH₃OH (18 mL) was stirred at ambient temperature for 1.0 h. The reaction mixture was acidified with 5% aqueous KHSO₄ and then extracted with ethyl acetate. The organic portion was then washed with brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 10:0.5:0.5 CH₂Cl₂/CH₃OH/HOAc) gave the carboxylic acid 56 as a colorless oil after azeotropic removal of residual HOAc with toluene.

10

15

TLC R_f = 0.40 (10:0.5:0.5 CH₂Cl₂/CH₃OH/HOAc); ¹H NMR (300 MHz, CDCl₃) δ 7.02 (bd, 1H), 4.35 (m, 1H), 4.12 (d, J = 16 Hz, 1H), 4.08 (m, 2H), 3.87 (d, J = 16 Hz, 1H), 3.32 (m, 2H), 2.69 (m, 2H), 2.56 (m, 2H), 2.36 (m, 1H), 2.00-1.25 (m, 11H), 1.45 (s, 9H), 1.03 (m, 2H).

20

25

Preparation of [3(R)-[2-Piperidin-4-yl)ethyl]-2-piperidone-1-lacetyl-3(R)-methyl- β -alanine (57)]

A solution of 56 (0.74g, 1.6 mmol), trifluoroacetic acid (10 mL), and CH₂Cl₂ (10 mL) was stirred at ambient temperature for 1.0 h. The

30

- 92 -

reaction mixture was then concentrated and the residual trifluoroacetic acid removed azeotropically with toluene. Flash chromatography (silica, 10:1:1 CH₃OH/NH₄OH/H₂O) afforded 57 as a white amorphous solid. Crystallization of 57 (100 mg) from hot ethanol (4.0 mL) gave 57 (45 mg) as crystals after filtration at ambient temperature.

mp = 240°(D); TLC Rf = 0.48 (10:1:1 CH₃OH/NH₄OH/H₂O);
¹H NMR (400 MHz, D₂O) δ 4.18 (m, 1H), 4.06 (d, J = 16 Hz, 1H), 3.95 (d, J = 16 Hz, 1H), 3.41 (m, 4H), 2.99 (m, 2H), 2.45 (m, 1H), 3.41 (m, 4H), 2.99 (m, 2H), 2.45 (m, 1H), 2.42 (dd, J = 18 and 6 Hz, 1H), 2.33 (dd, J = 18 and 7 Hz, 1H), 1.97 (m, 4H), 1.90-1.55 (m, 5H), 1.38 (m, 4H), 1.19 (d, J = 7 Hz, 3H).

Preparation of 1-[2-(N-Boc-Piperidin-4-yl)ethyl]-3-propen-2-yl-(1H-tetrahydropyrimidin-2-one) (59)

To a stirred suspension of 1H-tetrahydropyrimidin-2-one (1.0 g, 10 mM) in DMF (50 ml) was added a 1.0 molar solution of lithium bis(trimethylsilyl)amide (10 ml, 10 mM). After ½ hour, allyl bromide (1.0 ml, 1.17 mM) was added and stirring was continued for 1 hour. A second charge of lithium bis(trimethylsilyl)amide (10 ml, 10 mM) was added followed after ½ hour by the addition of (N-Boc-piperidin-4-yl) ethyl iodide (10). The reaction was stirred at 25°C overnight. The reaction mixture was poured into ice and 15% KHSO₄ (50 ml), extracted with ether (2 x 100 ml) washed with H₂O (2 x 100 ml), brine, dried over Na₂SO₄ and evaporated in vacuo. Flash chromatography on SiO₂ (ethyl acetate-hexane

- 93 -

1:1) afforded pure 59.

¹H NMR (300 MHz, CDCl₃) δ 1.14 (2H, m), 1.46 (9H, s),
1.74 (3H, m), 1.95 (2H, m) 2.68 (2H, t), 3.22 (4H,
m), 3.38 (2H, m), 3.95 (2H, m), 4.06 (2H, m), 5.13
(2H, dd).

Preparation of 1-[2-(N-Boc-Piperidin-4-yl)ethyl]-
3-acetaldehyde-(1H-tetrahydropyrimidin-2-one) (60)

To a stirred solution of 59 (430 mg, 1.27 mM)
in THF (7 ml), H₂O (5 ml) and sodium periodate (0.68
g, 3.19 mM) was added a 2.5% solution of osmium
tetroxide in 2-methyl-2-propanol (413 µl, 1.28 mM).
After stirring for 4 hours, ethyl acetate (70 ml) was
added and the mixture washed with 50% brine/10%
sodium sulfate (1:1) then with brine. The solution
was dried over Na₂SO₄ and evaporated in vacuo to give
60.

Preparation of 1-[2-(N-Boc-Piperidin-4-yl)ethyl]-3-
acetic acid-(1H-tetrahydropyrimidin-2-one) (61)

A solution of 60 (374 mg) in acetone (7 ml)
was cooled to -15°C then treated dropwise with Jones
reagent until an orange color persisted for 5
minutes. Ethyl acetate (60 ml) was added and the
solution washed with H₂O, brine, dried over Na₂SO₄,
then evaporated in vacuo to give 61.

¹H NMR (300 MHz, CDCl₃) δ 1.12 (2H, m), 1.45 (9H, s),
1.70 (2H, bd), 2.03 (2H, m), 2.70 (2H, bt), 3.37 (4H,
m), 3.95 (2H, m), 4.05 (2H, m).

- 94 -

Preparation of [1-[2-(N-Boc-Piperidin-4-yl)ethyl]-
(1H-tetrahydropyrimidin-2-one)-3]-acetyl-3(R)-(2-
phenylethyl) β -alaninemethylester (63)

5 A mixture of 61 (125 mg, 0.34 mM), (R)-3-(2-
phenylethyl) β -alanine methyl ester hydrochloride (83
mg, 0.34 mM) (62), 1-hydroxybenzotriazole hydrate
(48.3 mg, 0.35 mM), 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (70 mg, 0.37 mM) and
10 triethyl amine (107 μ l, 0.77 mM) in dry DMF (1.6 ml)
was stirred at 25°C for 18 hours. The reaction
mixture was poured into ice H₂O, extracted with ethyl
acetate (2 x 50 ml), washed with 10% citric acid,
brine, dried over Na₂SO₄ and evaporated in vacuo to
give 63.

15 ¹H NMR (300 MHz, CDCl₃) δ 1.14 (2H, m), 1.45 (9H, s),
1.70 (2H, m), 1.86 (2H, m), 2.02 (2H, m), 2.58 (2H,
d), 2.66 (3H, m), 3.36 (5H, m), 3.68 (2H, m), 3.93
(1H, d), 4.07 (2H, m), 7.02 (1H, m), 7.20 (2H, m),
20 7.29 (2H, m).

Preparation of 1-[2-(N-Boc-Piperidin-4-yl)ethyl]-
(1H-tetrahydropyrimidin-2-one)-3]-acetyl-3(R)-(2-
phenylethyl) β -alanine (64)

25 A solution of 63 (168 mg, 0.31 mM) in THF (15
ml) and H₂O (15 ml) was cooled to 0°C, treated with
1N LiOH (1.2 ml) then stirred at 25°C overnight. The
THF was evaporated at reduced pressure, the residue
acidified with 10% citric acid, extracted with ethyl
acetate (2 x 50 ml) washed with brine, dried over
30 Na₂SO₄ and evaporated in vacuo to give 64.

- 95 -

Preparation of [1-(2-piperidin-4-yl)ethyl]-[(1H-tetrahydropyrimidin-2-one)-3]-acetyl-3(R)-(2-phenylethyl) β -alanine (65)

5 A solution of 64 (128 mg) in methylene chloride (8 ml) and anisole (1.5 ml) was cooled to -20°C then treated with trifluoroacetic acid (8 ml) over a 5 minute period. The reaction mixture was stirred at -5°C for 1 hour then evaporated in vacuo. The residue was chromatographed on SiO₂ (ethanol-H₂O-NH₄OH, 10:1:1) to give 65.

Analysis Calc for C₂₄H₃₆N₄O₄•2.5H₂O

C, 57.84; H, 8.65; N, 11.73.

Found: C, 57.94; H, 8.39; N, 11.47.

15 Preparation of [1-(2-piperidin-4-yl)ethyl]-[(1H-tetrahydropyrimidin-2-one)-3]-acetyl-3(R)-(2-indol-3-yl)-ethyl β -alanine (66)

By following substantially the procedure described for preparing 63 but substituting for the 3(R)-(2-phenylethyl) β -alanine methyl ester hydrochloride described therein an equivalent amount of 3R-[2-(indol-3-ethyl) β -alanine ethyl ester and following the procedures described for preparing 64 and 65, there is obtained 66.

25 Analysis Calc for C₂₆H₃₇N₅O₄:

C, 56.3; H, 8.0; N, 12.6.

Found: C, 56.3; H, 7.9; N, 12.2.

30

- 96 -

Preparation of [1-(2-piperidin-4-yl)ethyl-(1H-tetrahydropyrimidin-2-one)-3]-acetyl-3(R)-methyl β -alanine (67)

5 By following substantially the procedure described for preparing 63 but substituting for the (R)-3-(2-phenylethyl) β -alanine methyl ester hydrochloride described therein an equivalent amount of ethyl 3(R)-methyl β -alanine hydrochloride and following the procedures described for preparing 64
10 and 65, there is obtained 67.

Preparation of [1-(2-piperidin-4-yl)ethyl]-[(1H-tetrahydropyrimidin-2-one)-3]-acetyl-2(R)-[butylsulfonylamino] β -alanine (68)

15 By following substantially the procedure described for preparing 63 but substituting for the (R)-3-(2-phenylethyl) β -alanine methyl ester hydrochloride described therein an equivalent amount of ethyl 2(S)-butylsulfonylamino β -alanine hydrochloride
20 and following the procedures described for preparing 64 and 65, there is obtained 68.

Preparation of Methyl 4(R)-Benzyl-2-oxazolidinone-succinate (70)

25 To a stirred solution of mono-methyl succinate 69 (3.7 g, 28.2 mmol), NEt_3 (4.0 mL, 28.2 mmol) and dry THF (160 mL) at -78°C was added trimethylacetyl chloride (3.6 mL, 28.2 mmol) dropwise. After 10 min, the cooling bath was removed
30 and replaced with an icebath. After 1.0 hour, the heterogeneous mixture was recooled to -78°C , and treated, via cannula addition, with lithium (R)-(+)-4-benzyl-2-oxazolidinone (28.2 mmol) in dry THF (43 mL), prepared by treating (R)-(+)-4-benzyl-2-

- 97 -

oxazolidinone (5.0 g, 28.2 mmol) in dry THF (43 mL) at -78°C with n-BuLi (17.8 mL, 28.2 mmol, 1.6 M/hexanes). After addition was complete, the reaction mixture was warmed to room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with H₂O, sat. NaHCO₃, 5% aqueous KHSO₄ and brine, dried MgSO₄ and concentrated. Flash chromatography (silica, 20% ethyl acetate/hexanes) gave 70 as a white crystalline solid.

TLC Rf=0.48 (30% ethyl acetate/hexanes);
¹H NMR (300 MHz, CDCl₃) δ 7.30 (m, 5H), 4.68 (m, 1H), 4.21 (m, 2H), 3.72 (s, 3H), 3.28 (m, 3H), 2.80 (dd, J=13 and 4Hz, 1H), 2.73 (m, 2H).

Preparation of Methyl 4(R)-Benzyl-2-oxazolidinone-2(R)-(2-cyanoethyl)succinate (71)

To a stirred solution of TiCl₄ (12.3 mL, 12.3 mmol, 1M/CH₂Cl₂) and dry CH₂Cl₂ (83 mL) at 0°C was added titanium (IV) isopropoxide (1.2 mL, 4.1 mmol). After 15 min, diisopropylethylamine (3.0 mL, 17.3 mmol) was added dropwise to form a dark brown solution. After 10 minutes, 70 (4.8 mg, 16.5 mmol) was added followed by continued stirring at 0°C for 1 hour. Acrylonitrile (4.3 mL, 66 mmol) was added dropwise to the dark solution followed by stirring at 0°C for 72 hours. The reaction mixture was quenched with sat. NH₄Cl at 0°C, then extracted with CH₂Cl₂. The combined organic extracts were washed with saturated NaHCO₃ and brine, dried MgSO₄ and concentrated. Flash chromatography (silica, 25% ethyl acetate/hexanes) gave 71 as a crystalline solid. TLC Rf=0.22 (30% ethyl acetate/hexanes);

- 98 -

¹H NMR (300 MHz, CDCl₃) δ 7.40-7.20 (m, 5H), 4.70 (m, 1H), 4.25 (m, 2H), 4.13 (m, 1H), 3.67 (s, 3H), 3.30 (dd, J=13 and 4Hz, 1H), 2.93 (dd, J=17 and 10Hz, 1H), 2.80 (dd, J=17 and 10Hz, 1H), 2.55 (dd, J=13 and 4Hz, 1H), 2.43 (t, J=7Hz, 2H), 2.10 (m, 1H), 1.90 (m, 1H).

Preparation of Methyl 4(R)-Benzyl-2-oxazolidinone-2(R)-(3-aminopropyl)succinate (72)

A mixture of 71 (2.0 g, 5.8 mmol), PtO₂ (0.8 g), CH₃OH (50 mL), and CHCl₃ (5 mL) were shaken on the Parr apparatus under a hydrogen atmosphere (60 PSI) at ambient temperature for 3 hours. The reaction mixture was filtered through a celite pad and then concentrated to furnish the crude amine•HCl 72 as a yellow oil.
TLC Rf=0.50 (CH₂Cl₂/CH₃OH/AcOH 9:1:1)

Preparation of Methyl [2-Piperidone-3(R)]acetate (73)

The crude amine•HCl 72 (2.0 g, ~5.8 mmol), acetonitrile (250 mL) and NaHCO₃ (5 g) were stirred overnight at ambient temperature. The reaction mixture was then filtered and the filtrate concentrated. Flash chromatography (silica, ethyl acetate) gave lactam 73 as a colorless crystalline solid.

TLC Rf=0.22 (ethyl acetate);

¹H NMR (300 MHz, CDCl₃) δ 5.82 (bs, 1H), 3.70 (s, 3H), 3.33 (m, 2H), 2.88 (dd, J=16 and 4Hz, 1H), 2.75 (m, 1H), 2.58 (dd, J=16 and 7Hz, 1H), 2.10-1.60 (m, 4H).

- 99 -

Preparation of Methyl [1-[N-Boc-2-(Piperidin-4-yl)-ethyl]-2-piperidone-3(R)]acetate (74)

To a stirred solution of 73 (1.1 g, 6.4 mmol) in anhydrous DMF (60 mL) at -15°C was added NaN(TMS)₂ (6.4 mL, 6.4 mmol, 1M/hexanes) dropwise followed by removal of the cooling bath. After 10 minutes the iodide 10 (2.3 g, 7.0 mmol) was added and stirring continued at ambient temperature for 4 hours. The reaction mixture was then diluted with ethyl acetate and washed with H₂O (2x) and brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 40% ethyl acetate/hexanes) gave 74 as an oil. TLC Rf=0.29 (40% ethyl acetate/hexanes).

15 Preparation of [1-[N-Boc-2-(piperidin-4-yl)ethyl]-2-piperidone-3(R)]acetic acid (75)

Utilizing the procedure for converting 49 to 50, 74 (0.44 g, 1.1 mmol) furnished 75 as an oil. TLC Rf=0.52 (CH₂Cl₂/CH₃OH/AcOH 9:0.5:0.5).

20 Preparation of [1-[N-Boc-2-(piperidin-4-yl)ethyl]-2-piperidone-3(R)]acetyl-3(R)-methyl-β-alanine ethyl ester (76)

Utilizing the procedure for converting 50 to 55, 75 (0.40 g, 1.1 mmol) was coupled to 54 (0.27 g, 1.6 mmol) to afford 76 as an oil after flash chromatography (silica, ethyl acetate). TLC Rf=0.20 (ethyl acetate).

30

- 100 -

Preparation of [1-[N-(Boc-2-(piperidin-4-yl)ethyl]-
2-piperidone-3(R)l]acetyl-3(R)-methyl-β-alanine (77)

Utilizing the procedure for converting 55 to
56, 76 (0.30 g, 0.64 mmol) gave 77 as an oil.

5 TLC R_f=0.24 (CH₂Cl₂/CH₃OH/AcOH 9:0.5:0.5);
1H NMR (400 MHz, CDCl₃) δ 6.93 (m, 1H), 4.32 (m, 1H),
4.06 (m, 2H), 3.35 (m, 2H), 3.29 (m, 2H), 2.70-2.50
(m, 6H), 2.38 (m, 1H), 2.00-1.20 (m, 9H), 1.45 (s,
9H), 1.27 (d, J=6Hz, 3H), 1.06 (m, 2H).

10

Preparation of [1-[2-(Piperidin-4-yl)ethyl]-2-
piperidone-3(R)-methyl-β-alanine (78)

Utilizing the procedure used to convert 56 to
57, 77 (0.24 g, 0.53 mmol) gave 78 as an amorphous
solid after flash chromatography (silica, 10:1:1
ethanol/H₂O/NH₄OH).

15

1H NMR (400 MHz, D₂O) δ 4.19 (m, 1H), 3.40 (m, 6H),
3.00 (m, 2H), 2.70 (m, 1H), 2.64 (m, 1H), 2.47 (m,
2H), 2.30 (dd, J=14 and 8Hz, 1H), 2.00 (m, 2H), 1.92
(m, 2H), 1.79 (m, 1H), 1.61 (m, 4H), 1.45 (m, 2H),
1.18 (d, J=7Hz, 3H).

20

Preparation of N-Cbz-Gly-3(R)-methyl-β-alanine ethyl
ester (79)

25

A stirred solution of Cbz-Gly (0.94 g, 4.5
mmol), 4-methylmorpholine (1.1 mL, 4.9 mmol), and
ethyl acetate (50 mL) at -15°C was treated with
isobutyl chloroformate (0.61 mL, 4.7 mmol) in one
portion. After 15 min, 54 (0.75 g, 4.5 mmol) in
ethyl acetate (1 mL) was added followed by warming to
30 ambient temperature overnight. The reaction mixture
was then washed with 1M NaHSO₄, brine, sat. NaHCO₃
and brine, dried (MgSO₄), and concentrated to afford
79 as a yellow oil.

- 101 -

¹H NMR (300 MHz, CDCl₃) δ 7.48 (m, 5H), 6.73 (m, 1H), 5.58 (m, 1H), 5.13 (s, 2H), 4.48 (m, 1H), 4.30 (q, J=7Hz, 2H), 3.95 (m, 2H), 2.62 (m, 2H), 1.37 (t, J=7Hz, 3H).

5

Preparation of Gly-3(R)-methyl-β-alanine ethyl ester
acetic acid salt (80)

A mixture of 79 (1.4 g, 4.5 mmol), 10% AcOH/CH₃OH (50 mL), and 20% Pd(OH)₂ (0.14 g) was shaken on the Parr apparatus under a hydrogen atmosphere (60 PSI) overnight. After 24 hours the reaction mixture was filtered through a celite pad and the filtrate concentrated. Flash chromatography (silica, 5:3:1 CH₂Cl₂/ethanol/AcOH) to give 80 as an amorphous solid. TLC Rf=0.41 (5:3:1 CH₂Cl₂/ethanol/AcOH).

15

Preparation of 4(S)-Benzyl-2-oxazolidinone-4-(N-Boc-piperidin-4-yl)-2(R)-(prop-2-ene)butyrate (81)

To a stirred solution of 45 (2.5 g, 5.8 mmol) in THF (50 ml) at -78°C was added lithium bis(trimethylsilyl)amide (7.0 mL, 7.0 mmol, 1M/hexanes) followed by allyl bromide (2.5 mL, 29 mmol). The cooling bath was then removed and the reaction stirred at 0°C for 1.5 hours. The reaction was quenched with sat. NH₄Cl, then diluted with EtOAc followed by washing with sat. NaHCO₃, 5% KHSO₄, and brine, drying (MgSO₄) and concentration. Flash chromatography (silica, 15% EtOAc/hexanes) afforded 81 as a colorless oil. TLC Rf=0.53 (30% EtOAc/hexanes);

20

25

30

- 102 -

¹H NMR (300 MHz, CDCl₃) δ 7.40-7.20 (m, 5H), 5.82 (m, 1H), 5.10 (m, 2H), 4.80 (m, 1H), 4.20 (m, 2H), 4.07 (m, 2H), 3.90 (m, 1H), 3.31 (dd, J=13 and 3Hz, 1H), 2.68 (m, 2H), 2.48 (m, 1H), 2.35 (m, 1H), 1.90-1.20 (m, 7H), 1.47 (s, 9H), 1.10 (m, 2H).

Preparation of 4-(N-Boc-Piperidin-4-yl)-2(R)-(prop-2-ene)butyric acid (82)

To a stirred solution of **81** (1.8g, 3.8mmol), 30% H₂O₂ (8.5 mL, 83 mmol), THF (41 mL) and H₂O (12mL) at ambient temperature was added LiOH (14 mL, 14 mmol, 1N). After 2h the excess LiOH was quenched with 10% NaHSO₄ dropwise at 0°C. The reaction was then acidified with 5% KHSO₄ and extracted with EtOAc. The EtOAc portion was then washed with brine, dried (MgSO₄), and concentrated to give **82** as a colorless oil.

TLC R_f = 0.79 (10% CH₃OH/EtOAc).

Preparation of [4-(N-Boc-Piperidin-4-yl)-2(R)-(prop-2-ene)butyrate]-Gly-3(R)-methyl-β-alanine ethyl ester (83)

Utilizing the procedure for converting **50** to **55**, **82** (1.3 g, 2.5 mmol) was coupled to **80** (0.62 g, 2.5 mmol) to give **83** after flash chromatography (silica, 10% isopropanol/hexanes).

TLC R_f=0.50 (20% isopropanol/hexanes);

¹H NMR (300 MHz, CDCl₃) δ 6.67 (bd, J=8Hz, 1H), 6.37 (m, 1H), 5.72 (m, 1H), 5.02 (m, 1H), 4.35 (m, 1H), 4.13 (q, J=7Hz, 2H), 4.03 (m, 1H), 3.88 (m, 2H), 2.63 (m, 2H), 2.51 (m, 2H), 2.35 (m, 1H), 2.20 (m, 2H), 1.70-1.20 (m, 7H), 1.44 (s, 9H), 1.26 (t, J=7Hz, 3H), 1.07 (m, 2H).

- 103 -

Preparation of [3-[2-(N-Boc-Piperidin-4-yl)ethyl]-5-hydroxy-2-pyrrolidinone-1]acetyl-3(R)-methyl-β-alanine ethyl ester (84)

5 To a solution of 83 (0.74 g, 1.5 mmol), THF (12.2 mL), H₂O (9.2 mL), and NaIO₄ (0.82 g, 3.8 mmol) was added OsO₄ (0.96 mL, 80 μmol; 2.5% tert-butanol) at ambient temperature. After 2.0 hours, the reaction mixture was diluted with ether and then washed with H₂O, 10% aqueous Na₂S₂O₃, and brine, dried (MgSO₄),
10 and concentrated to give 84 as a yellow oil. TLC R_f=0.26 (20% isopropanol/hexanes).

Preparation of [3-[2-(N-Boc-Piperidin-4-yl)ethyl]-5-hydroxy-2-pyrrolidinone-1]acetyl-3(R)-methyl-β-alanine (85)

15 Utilizing the procedure for converting 55 to 56, 84 (0.73 g, 1.5 mmol) gave 85 as a pale yellow foam.

20 ¹H NMR (300 MHz, CDCl₃) δ 5.23 (d, J=5Hz, 1H), 4.58 (d, J=16Hz, 1H), 4.32 (m, 1H), 4.05 (m, 2H), 3.70 (d, J=16Hz, 1H), 2.80-2.40 (m, 6H), 2.22 (m, 1H), 2.00-1.00 (m, 9H), 1.45 (s, 9H), 1.27 (d, J=7Hz, 3H).

25 Preparation of [3-[2-(Piperidin-4-yl)ethyl]-2-pyrrolidinone-1]acetyl-3(R)-methyl-β-alanine (86)

A stirred solution of 85 (0.61 g, 1.3 mmol) in CH₂Cl₂ (50 mL) at ambient temperature was treated with a solution of CF₃CO₂H (5.8 mL) and triethylsilane (0.8 mL, 5.2 mmol). After 2.0 h the reaction mixture was concentrated followed by azeotropic removal of residual CF₃CO₂H with toluene. Flash chromatography (silica, 10:1:1 ethanol/H₂O/NH₄OH) gave 86 as a colorl ss solid.

- 104 -

TLC Rf=0.17 (9:1:1 ethanol/H₂O/NH₄OH);

¹H NMR (300 MHz, CD₃OD) δ 4.20 (m, 1H), 3.97 (d, J=17Hz, 1H), 3.85 (d, J=17Hz, 1H), 3.40 (m, 4H), 2.95 (m, 2H), 2.52 (m, 1H), 2.30 (m, 2H), 2.00-1.30 (m, 11H), 1.20 (d, J=7Hz, 3H).

Preparation of 2-(2,3,4,5,6-Tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)prop-2-ene (88)

To a solution of 87 (J.O.C. 52, p. 2162 (1987) E.H. White, H.M. Lim) (0.35 g, 2.6 mmol) in DMF at 0°C was added NaN(TMS)₂ (3.9 mL, 3.9 mmol); 1M/hexanes) dropwise. After 30 min, allyl bromide (0.45 mL, 5.2 mmol) was added in one portion followed by continued stirring for 30 min. The reaction mixture was diluted with ethyl acetate and washed with sat. NH₄Cl and brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 30% ethyl acetate/hexanes) gave 88 as a colorless oil.

TLC Rf=0.29 (30% ethyl acetate/hexanes);

¹H NMR (300 MHz, CDCl₃) δ 5.80 (m, 1H), 5.25 (m, 2H), 3.78 (m, 2H), 3.30 (m, 2H), 3.02 (m, 2H), 2.21 (m, 2H), 1.68 (m, 2H).

Preparation of 2-[6-[2-(N-Boc-Piperidin-4-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]-prop-2-ene (89)

A stirred solution of 88 (0.34 g, 1.93 mmol) in THF (10 mL) at -78°C was treated dropwise with n-BuLi (1.45 mL, 2.3 mmol; 1.6 M/hexanes). After 30 min the reaction mixture was treated sequentially with 1-methyl-2-pyrrolidinone (1 mL) and 10 (0.86 g, 2.7 mmol) in THF (10 mL), followed by warming to -23°C. After 2 hours at -23°C the reaction was quenched with

- 105 -

saturated NH_4Cl then diluted with ethyl acetate and washed with H_2O and brine, dried (MgSO_4), and concentrated. Flash chromatography (silica, 30% ethyl acetate/hexanes) gave 89 as a crystalline solid. TLC $R_f=0.27$ (30% ethyl acetate/hexanes);

^1H NMR (400 MHz, CDCl_3) δ 5.80 (m, 1H), 5.25 (m, 2H), 4.07 (m, 2H), 3.78 (m, 2H), 3.34 (m, 2H), 3.17 (m, 1H), 3.02 (m, 1H), 2.82 (m, 2H), 2.66 (m, 2H), 2.24–2.04 (m, 3H), 1.89 (m, 1H), 1.70–1.35 (m, 7H), 1.08 (m, 2H).

Preparation of 2-[6-[2-(N-Boc-Piperidin-4-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]-acetaldehyde (90)

To a stirred solution of 89 (0.50 g, 1.29 mmol), THF (16 mL), H_2O (12 mL), and NaIO_4 (0.69 g, 3.2 mmol) was added OsO_4 (1 mL, 0.1 mmol; 2.5 %/tert-butanol) to effect a white precipitate. After 3.0 h, the reaction mixture was diluted with ethyl acetate and washed with H_2O , 5% KHSO_4 , sat. NaHCO_3 and brine, dried (MgSO_4), and concentrated to give aldehyde 90 as an oil.

^1H NMR (400 MHz, CDCl_3) δ 9.64 (s, 1H), 4.08 (m, 2H), 4.00 (d, $J=17\text{Hz}$, 1H), 3.89 (d, $J=17\text{Hz}$, 1H), 3.62 (m, 1H), 3.14 (m, 1H), 2.96 (m, 1H), 2.66 (m, 2H), 2.20 (m, 1H), 2.08 (m, 1H), 2.00–1.35 (m, 9H), 1.10 (m, 2H).

Preparation of 2-[6-[2-(N-Boc-Piperidin-2-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]-acetic acid (91)

A stirred solution of 90 (0.44 g, 1.13 mmol) in acetone (10 mL) at 0°C was treated with Jones Reagent (1.0 mL) in 3 portions. After 5 min, excess

- 106 -

Jones Reagent was quenched with i-propanol and then diluted with H₂O. The reaction mixture was then extracted with ethyl acetate and the organic extract washed with brine, dried (MgSO₄), and concentrated. Flash chromatography (silica, 20:1:1 CH₂Cl₂/CH₃OH/AcOH) gave 91 as a light yellow oil. TLC Rf=0.45 (20:1:1 CH₂Cl₂/CH₃OH/AcOH).

Preparation of 2-[6-[2-(N-Boc-Piperidin-4-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]-acetyl-3(R)-methyl-B-alanine ethyl ester (92)

Utilizing the procedure for converting 50 to 55, 91 (98 mg, 0.24 mmol) was coupled to 54 (120 mg, 0.71 mmol) to afford 92 as a yellow oil after flash chromatography (silica, ethyl acetate).

TLC Rf=0.28 (ethyl acetate);

¹H NMR (300 MHz, CDCl₃) δ 7.08 (m, 1H), 4.37 (m, 1H), 4.08 (m, 2H), 3.89 (d, J=17Hz, 1H), 3.77 (d, J=17Hz, 1H), 3.60 (m, 1H), 3.15 (m, 1H), 2.88 (m, 1H), 2.68 (m, 2H), 2.52 (m, 2H), 2.20-1.00 (m, 13H), 1.27 (t, J=7Hz, 3H), 1.25 (t, J=7Hz, 3H).

Preparation of 2-[6-[2-(N-BOC-Piperidin-4-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]-acetyl-3(R)-methyl-B-alanine (93).

Utilizing the procedure for converting 55 to 56, 92 (76 mg, 0.15 mmol) gave 93 as an oil.

TLC Rf = 0.42 (20:1:1 CH₂Cl₂/CH₃OH/AcOH);

¹H NMR (300 MHz, CDCl₃) δ 7.20 (m, 1H), 4.39 (m, 1H), 4.10 (q, J=7 Hz, 2H), 4.08 (m, 2H), 3.92 (d, J=17 Hz, 1H), 3.74 (m, 1H), 3.53 (m, 1H), 3.15 (m, 1H), 2.90 (m, 1H), 2.77 (m, 2H), 2.59 (m, 2H), 2.10 (m, 1H), 2.10-1.10 (m, 12H), 1.27 (t, J=7 Hz, 3H), 1.25 (t, J=7 Hz, 3H).

- 107 -

Preparation of 2-[6-[2-(Piperidin-4-yl)ethyl]-(3,4,5,6-tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)]acetyl-3-(R)-methyl-β-alanine (94).

Utilizing the procedure for converting 56 to 57, 93 (61 mg, 0.12 mmol) gave 94 as an off-white solid after flash chromatography (silica, 10:1:1 ethanol/NH₄OH/H₂O).

TLC R_f = 0.26 (10:1:1 ethanol/NH₄OH/H₂O);

¹H NMR (300 MHz, D₂O) δ 4.08 (m, 1H), 3.71 (m, 2H), 3.40 (m, 1H), 3.29 (m, 2H), 3.14 (m, 2H), 2.83 (m, 2H), 2.25 (m, 2H), 2.12 (m, 1H), 1.90-1.20 (m, 12H), 1.05 (d, J=7 Hz, 3H).

1-[2-(N-BOC-piperidin-4-yl)ethyl]-3-propanol-2-pyrrolidinone (95)

A solution of 20 (1.20 g, 3.6 mmol) in THF (3 ml) was added to a solution of borane-dimethyl sulfide (3.6 mmol) in 3 ml THF at 0°C and this was stirred for 2.5 hr at 0°. Then, H₂O (0.15 ml), 10N aqueous NaOH solution (0.65 ml), THF (1 ml), and C₂H₅OH (0.36 ml) were added at 0° and with stirring the reaction mixture was warmed to 23° and treated with 30% H₂O₂ (0.36 ml). This solution was heated to 55°C and stirred for 2 hours. The reaction mixture was cooled, saturated with K₂CO₃ and the organic phase was separated, dried (MgSO₄) and the solvent removed. The resulting residue was purified by flash chromatography on silica gel eluting with 10% MeOH/EtOAc to give 95. R_f 0.3 (silica gel, 10% MeOH/EtOAc).

- 108 -

1-[2-(N-BOC-piperidin-4-yl)ethyl]-3-propanoic-acid-2-pyrrolidinone (96)

A solution of 95 (1.14 mmol) in acetone (5 ml) was cooled to -15° and treated with Jones reagent until the color remained amber/brown. The reaction mixture was diluted with saturated NaHCO₃ solution to pH 9 and this was extracted with EtOAc. The aqueous phase was acidified to pH 3 with KHSO₄ solution and extracted with several portions of EtOAc. The combined organic extracts were dried (MgSO₄) and the solvent removed to give 96. R_f 0.3 (silica gel, 9/1/1 CH₂Cl₂/MeOH/HOAc).

[1-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyrrolidinone-3]propanoyl-β-alanine ethyl ester (97)

A solution of 96 (0.55 mmol), β-alanine ethyl ester•HCl (0.825 mmol), N-methylmorpholine (1.65 mmol) in CH₃CN (5 ml) at 23° was treated with BOP (0.825 mmol) and the resulting solution was stirred for 48 hrs. The reaction mixture was diluted with EtOAc, washed with 10% KHSO₄, brine, H₂O, brine, dried (MgSO₄) and the solvent removed. The residue was purified by flash chromatography on silica gel eluting with 30% acetone/hexane to give 97 as a clear oil. R_f 0.25 (silica gel, 30% acetone/hexane).

[1-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyrrolidinone-3]propanoyl-β-alanine (98)

A solution of 97 (0.29 mmol), LiOH•H₂O (1.45 mmol), THF/MeOH/H₂O (1:1:1, 3 ml) was stirred for 2 hours. This was diluted with EtOAc and washed with 10% KHSO₄, H₂O, brine and dried (MgSO₄). Solvent removal gave 98 as an oil. R_f 0.5 (silica gel, 9/1/1 CH₂Cl₂/MeOH/HOAc).

- 109 -

[1-[2-(Piperidin-4-yl)ethyl]-2-pyrrolidinone-3]propanoyl-β-alanine •HCl (99)

5 A solution of 98 (0.18 mmol) in EtOAc (2 ml) was cooled to -78° and treated with HCl gas. After 0.5 hr the solvent was removed to give 99 as a white solid. Rf 0.22 (silica gel, 10/1/1 EtOH, NH₄OH, H₂O).

Preparation of N-BOC-4-piperidine methyl iodide (101)

10 Utilizing the procedure for converting 9 to 10, 100 (12.3 g, 57 mmol) (Carr et al., EP 317997, May 31, 1989), gave 101 after flash chromatography (silica gel, 15% EtOAc/hexane). Rf 0.38 (silica gel, 10% EtOAc/hexanes).

15 ¹H NMR (300 MHz, CDCl₃) δ 1.15 (2H, m), 1.48 (9H, s), 1.62 (1H, m), 1.84 (2H, m), 2.70 (2H, m), 3.11 (2H, m), 4.12 (2H, m).

Preparation of N-BOC-piperidinemethyltriphenylphosphonium iodide (102)

20 A solution of 101 (5.1 g, 15.7 mmol), CH₃CN (75 mL), and triphenylphosphine (4.5 g, 17.3 mmol) was heated at 80°C for 60 h. The cooled reaction mixture was concentrated and the residual oil triturated with ether, then placed under vacuum to give 102 as a yellow foam.

25 ¹H NMR (CDCl₃, 300 MHz) δ 7.31 (m, 15H), 4.10 (m, 2H), 3.97 (m, 2H), 2.69 (m, 2H), 2.00-1.10 (m, 5H), 1.48 (s, 9H).

30

- 110 -

Preparation of 3-[2-(N-BOC-piperidin-4-yl)ethylene]-2-
(methoxy)pyridine (104)

To a suspension of 102 (5.0 g, 8.5 mmol) in
dry THF at 0°C was added $\text{NaN}(\text{TMS})_2$ (9.4 mL, 9.4 mmol,
5 1M/hexanes) dropwise. After 15 min. a solution of 103
(0.97 g, 7.0 mmol) (Tetrahedron Letters (1988) 29,
773) in THF (3 mL) was added dropwise to the
yellow/orange homogeneous reaction mixture. After 1h
the cooling bath was removed followed by continued
10 stirring for 30 min. The reaction was quenched with
 H_2O and ether. The aqueous phase was reextracted with
ether, the organic layers combined and then washed
with brine, dried (Na_2SO_4) and concentrated. Flash
chromatography (silica, 15% ethyl acetate/hexanes)
15 gave 104 as a colorless oil.

TLC Rf = 0.15 (10% ethyl acetate/hexanes), ^1H NMR (300
MHz, CDCl_3) δ 8.09 (dd, J=5 and 2 Hz, 1H), 7.42 (dd,
J=7 and 2Hz, 1H), 6.87 (dd, J=7 and 5 Hz, 1H), 6.37
20 (d, J = 12 Hz, 1H), 5.58 (dd, J=12 and 10 Hz, 1H),
4.10 (m, 2H), 3.95 (s, 3H), 2.70 (m, 2H), 2.50 (m,
1H), 1.80-1.20 (m, 4H), 1.47 (s, 9H).

Preparation of 3-[2-(N-BOC-piperidin-4-yl)ethyl]-2-
methoxypyridine (105)

25 A mixture of 104 (1.4 g, 4.3 mmol), ethyl
acetate (22 mL) and 10% Pd/C (0.27 g, 20%/wt) was
stirred under a hydrogen atmosphere (1 atm) at ambient
temperature for 4 h. The reaction mixture was
30 filtered through a celite pad and the filtrate
concentrated to give 105 as a cloudy colorless oil.

- 111 -

TLC Rf = 0.17 (10% ethyl acetate/hexanes); ^1H NMR (CDCl₃, 300 MHz) δ 8.02 (dd, J=5 and 2 Hz, 1H), 7.36 (dd, J=7 and 2 Hz, 1H), 6.80 (dd, J=7 and 5 Hz, 1H), 4.10 (m, 2H), 3.94 (s, 3H), 2.69 (m, 2H), 2.58 (m, 2H), 1.72 (m, 2H), 1.55-1.35 (m, 3H), 1.48 (s, 9H), 1.13 (m, 2H).

Preparation of 3-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyridon-1-yl (106)

To a solution of 105 (0.81 g, 2.5 mmol) in dry CH₃CN (13 mL) was added NaI (0.94 g, 6.3 mmol) followed by chlorotrimethylsilane (0.80 mL, 6.3 mmol). The resulting opaque yellow solution was heated at 60°C for 2.0 h. The cooled reaction mixture was quenched with methanol (50 mL), stirred for 10 min. and then concentrated. The residue was dissolved in dioxane/H₂O (6.7 mL/3.3 mL) then treated with 1N NaOH (5.0 mL, 5.0 mmol). The solution was cooled to 0°C and then treated with BOC₂O (1.1 g, 5.0 mmol) followed by removal of the cooling bath. After stirring overnight the dioxane was evaporated and the residue diluted with H₂O (10 mL) and ethyl acetate (50 mL), followed by acidification to pH ~ 1.0 with 20% KHSO₄. The organic phase was separated and then washed with H₂O and brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 2:1 CH₂Cl₂/acetone) gave 106 as a pale yellow solid.

TLC Rf = 0.19 (2:1 CH₂Cl₂/acetone); ^1H NMR (CDCl₃, 400 MHz) δ 7.30 (m, 3H), 6.23 (t, J=7 Hz, 1H), 4.04 (m, 2H), 2.69 (m, 2H), 2.57 (m, 2H), 1.74 (m, 2H), 1.56 (m, 2H), 1.48 (m, 1H), 1.47 (s, 9H), 1.16 (m, 2H).

- 112 -

Preparation of Ethyl {3-[2-(N-BOC-piperidin-4-yl)-
ethyl]-2-pyridon-yl}acetate (107)

To a stirred solution of 106 (0.44 g, 1.4 mmol) in dry DMF (7.2 mL) at 0°C was added NaN(TMS)₂ (2.1 mL, 2.1 mmol, 1M/hexanes) dropwise. After 30 min. ethyl bromoacetate (0.79 mL, 7.2 mmol) was added dropwise to the reaction mixture. After an additional hour the reaction was diluted with ethyl acetate and then washed with H₂O, 5% KHSO₄, sat. NaHCO₃ and brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 45% ethyl acetate/hexanes) gave 107 as a colorless oil.

TLC Rf = 0.33 (60% ethyl acetate/hexanes); 7.20 (dd, J=6 and 1 Hz, 1H), 7.11 (dd, J=7 and 2 Hz, 1H), 6.15 (t, J=7 Hz, 1H), 4.62 (s, 2H), 4.24 (q, J=7 Hz, 2H), 4.04 (m, 2H), 2.69 (m, 2H), 2.55 (m, 2H), 1.72 (m, 2H), 1.52 (m, 2H), 1.78 (m, 1H), 1.48 (s, 9H), 1.13 (m, 2H).

Preparation of {3-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyridon-1-yl} acetic acid (108)

Utilizing the procedure for converting 55 to 56, 107 (0.51 g, 1.3 mmol) gave 108 as a colorless foam.

TLC RF = 0.58 (9:1:1 CH₂Cl₂/CH₃OH/HOAc).

- 113 -

Preparation of {3-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyridon-1-yl}acetyl-3(R)-methyl-β-alanine ethyl ester
(109)

5 Utilizing the procedure for converting 15 to 16, 108 (0.15 g, 0.41 mmol) gave 109 as a waxy solid after flash chromatography (silica, ethyl acetate).

10 TLC Rf = 0.38 (ethyl acetate) ¹H NMR (CDCl₃, 400 MHz) δ 7.24 (dd, J=7 and 2Hz, 1H), 7.21 (dd, J=7 and 2 Hz, 1H), 7.07 (bd, J=8 Hz, 1H), 6.19 (t, J=7Hz, 1H), 4.51 (s, 2H), 4.30 (m, 1H), 4.08 (q, J=7Hz, 2H), 4.08 (m, 2H), 2.69 (m, 2H), 2.55 (m, 2H), 1.72 (m, 2H), 1.51 (m, 2H), 1.45 (s, 9H), 1.43 (m, 1H), 1.23 (t, J=7Hz, 3H), 1.22 (d, J=7Hz, 3H), 1.13 (m, 2H).

15 Preparation of {3-[2-(N-BOC-piperidin-4-yl)ethyl]-2-pyridon-1-yl}acetyl-3(R)-methyl-β-alanine (110)

Utilizing the procedure for converting 55 to 56, 109 (0.19 g, 0.41 mmol) gave 110 as a colorless oil.

20 TLC = 0.59 (9.5/0.5/0.5 CH₂Cl₂/CH₃OH/HOAc).

Preparation of {3-[2-(Piperidin-4-yl)ethyl]-2-pyridon-1-yl}acetyl-3(R)-methyl-β-alanine (111)

25 A solution of 103 (0.18 g, 0.40 mmol), CH₂Cl₂ (2.0 mL), anisole (86 μL, 0.80 mmol), and trifluoroacetic acid (2.0 mL) was stirred at -15° for 15 min. The yellow reaction mixture was concentrated and the residual trifluoroacetic acid removed azeotropically with toluene. Flash chromatography
30 (silica, 10/1.3/1.3 ethanol/NH₄OH/H₂O) give 111 as a white amorphous solid.

- 114 -

TLC Rf = 0.17 (10:1:1 ethanol/NH₄OH/H₂O); ¹H NMR (D₂O, 400 MHz) δ 7.57 (dd, J=7 and 1 Hz, 1H), 7.49 (dd, J=7 and 1Hz, 1H), 6.51 (t, J=7Hz, 1H), 4.66 (m, 2H), 4.20 (m, 1H), 3.42 (m, 2H), 2.97 (m, 2H), 2.59 (m, 2H), 2.46 (dd, j=14 and 6 Hz, 1H), 2.32 (dd, J=14 and 7Hz, 1H), 2.00 (m, 2H), 1.60 (m, 3H), 1.42 (m, 2H).

Preparation of N-Cbz-4-piperidineethanol (112)

To a stirred solution of 4-piperidineethanol 8 (15 g, 0.12 mol), THF (500 mL), and diisopropylethylamine (40.5 mL, 0.23 mol) at 0°C was added benzyl chloroformate (16.5 mL, 0.12 mmol). After 1 h at 0°C the reaction mixture was diluted with ethyl acetate and then washed with H₂O (2x), 10% KHSO₄, and brine, dried (MgSO₄), and concentrated to give 112 as a colorless oil.

TLC Rf = 0.60 (ethyl acetate); ¹H NMR (300 MHz, CDCl₃) δ 7.35 (m, 5H), 5.13 (s, 2H), 4.18 (m, 2H), 3.70 (q, J=7Hz, 2H), 2.80 (m, 2H), 1.80-1.50 (m, 5H), 1.19 (m, 2H).

Preparation of N-Cbz-4-piperidine ethyl iodide (113)

Utilizing the procedure for converting 9 to 10, 112 (30.6 g, 0.12 mol) gave 113 as a colorless oil after flash chromatography (silica, 10% ethyl acetate/hexanes).

30

- 115 -

Preparation of 1-[2-(N-Cbz-piperidin-4-yl)ethyl]-
(2-pyrrolidinone) (114).

To a stirred solution of 2-pyrrolidinone (11.0 g, 0.13 mol) in dry DMF (500 mL) at ambient temperature was added $\text{NaN}(\text{TMS})_2$ (129 mL, 129 mmol, 1M/THF) dropwise. After 10 min, the iodide 113 (24.1 g, 64.6 mmol) in DMF (50 mL) was added to the reaction vessel. After 1 hour, the reaction mixture was diluted with ethyl acetate and then washed with H_2O , sat. NaHCO_3 and brine, dried (MgSO_4) and concentrated. Flash chromatography (silica, ethyl acetate) gave 114 as a colorless oil.

TLC R_f =0.16 (ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 7.40-7.20 (m, 5H), 5.12 (s, 2H), 4.19 (m, 2H), 3.34 (m, 2H), 2.77 (m, 2H), 2.40 (m, 2H), 2.04 (m, 2H), 1.74 (m, 2H), 1.47 (m, 3H), 1.15 (m, 2H).

Preparation of 1-[2-(N-Cbz-piperidin-4-yl)ethyl]-3-
propen-2-yl-(2-pyrrolidinone) (115).

To a stirred solution of 114 (8.0 g, 24.2 mmol), and THF (180 mL) at -78°C was added LDA (50 mL, 25 mmol, 0.5M/THF) dropwise. After 15 min. allyl bromide (2.3 mL, 26.6 mmol) was added. After 1.0 hour, the reaction mixture was allowed to warm to 0°C over a 10 min. period. The reaction mixture was diluted with ethyl acetate and then washed with 5% KHSO_4 and brine, dried (MgSO_4) and concentrated. Flash chromatography (silica, 50% ethyl acetate/hexanes) gave 115.

- 116 -

TLC Rf=0.65 (ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 7.35 (m, 5H), 5.80 (m, 1H), 5.12 (m, 2H), 4.18 (m, 2H), 3.33 (m, 4H), 2.80 (m, 2H), 2.56 (m, 2H), 2.20 (m, 2H), 1.78 (m, 2H), 1.48 (m, 3H), 1.20 (m, 2H).

Preparation of 1-[2-(N-Cbz-piperidin-4-yl)-ethyl]-3-acetic acid-2-pyrrolidinone (116).

Utilizing the procedure for converting 14 to 15, 115 (4.7 g, 12.7 mmol) gave 116 as a light brown oil after flash chromatography (silica, $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{HOAc}$ 9.5:0.5:0.5).

TLC Rf=0.63 ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{HOAc}$ 9.0:0.5:0.5); ^1H NMR (300 MHz, CDCl_3) δ 7.37 (m, 5H), 5.15 (s, 2H), 4.18 (m, 2H), 3.37 (m, 4H), 3.00-2.30 (m, 5H), 1.77 (m, 2H), 1.46 (m, 3H), 1.18 (m, 2H).

Preparation of [1-[2-(N-Cbz-piperidin-4-yl)ethyl]-2-pyrrolidinone-3]acetyl-2-aminoethylphosphonic acid (117).

A solution of 116 (388 mg, 1.0 mmol), Et_3N (0.14 mL, 1.0 mmol), and dry dioxane (5 mL) at 0°C was treated with isobutyl chloroformate (0.13 mL, 1.0 mmol). The reaction mixture was warmed until the dioxane melted. A solution of 2-aminoethylphosphonic acid (125 mg, 1.0 mmol), Na_2CO_3 (106 mg) and H_2O (2 mL) was added to the reaction vessel at ambient temperature. After 4 hours the dioxane was evaporated and the residue acidified with 1N HCl. The mixture

- 117 -

was washed with ethyl acetate (3x). The aqueous portion was concentrated to dryness to afford crude 117.

TLC Rf=0.15 (9:1.0:1.0 CH₂Cl₂/CH₃OH/HOAc).

5

Preparation of [1-[2-(piperidin-4-yl)ethyl]-2-pyrrolidinone-3]acetyl-2-aminoethylphosphonic acid (118).

10 The crude phosphonic acid 117 (464 mg) was dissolved in 10% HOAc/CH₃OH (20 mL), then Pd(OH)₂ (50 mg) was added and the mixture hydrogenated on the Parr apparatus (50 PSI) overnight. After 20 hours the reaction mixture was filtered through a celite pad and the filtrate concentrated. Flash chromatography
15 (silica, 8:1:1 CH₃OH/H₂O/NH₄OH) gave 118 as an amorphous solid.

TLC Rf=0.14 (8:1:1 CH₃OH/H₂O/NH₄OH); ¹H NMR (300 MHz, H₂O) δ 3.40 (m, 8H), 3.18 (m, 1H), 2.92 (m, 3H), 2.60 (m, 1H), 2.38 (m, 1H), 2.26 (m, 1H), 1.97
20 (m, 2H), 1.79 (m, 3H), 1.56 (m, 2H), 1.40 (m, 2H).

Preparation of (4-N-Cbz-amino)cyclohexane carboxylic acid methyl ester (121).

25 To a suspension of 120 (17.5 g, 0.12 mol) in CH₃OH (150 mL) at -10°C was added thionyl chloride (13.4 mL, 0.18 mol) portionwise over a 5 min. period, followed by removal of the cooling bath. After 16 hours the resulting solution was concentrated and the residue dissolved in DMF (150 mL), cooled to 0°C then
30 treated sequentially with N(i-Pr)₂Et (52 mL, 0.3 mol) and benzyl chloroformate (18.6 mL, 0.13 mol). The

- 118 -

cooling bath was removed and after 24 hours the reaction mixture was concentrated. The residue was diluted with ethyl acetate and then washed with saturated NaHCO_3 , 5% KHSO_4 and brine, dried (MgSO_4) and concentrated. Flash chromatography (silica, 20% ethyl acetate/hexanes) gave 121 as a waxy crystalline solid.

TLC R_f =0.34, 0.39 (30% ethyl acetate/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.38 (m, 5H), 5.09 (bs, 2H), 4.68 (m, 0.5H), 4.59 (m, 0.5H), 3.72 (m, 0.5H), 3.68 (s, 1.5H), 3.67 (s, 1.5H), 3.50 (m, 0.5H), 2.45 (m, 1H), 2.13-1.50 (m, 8H).

Preparation of (4-N-Cbz-amino)[1-(propen-3-yl)]cyclohexane carboxylic acid methyl ester (122).

To a stirred solution of 121 (1.0 g, 3.4 mmol) in dry THF (17.2 mL) at -78°C was added LDA (4.3 mL, 8.6 mmol, 2.0M) dropwise. The cooling bath was warmed to -40°C . After stirring at -40°C for 15 min. the reaction mixture was recooled to -78°C and then treated sequentially with 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H-pyrimidinone) (2.0 mL, 17 mmol) and allyl bromide (0.44 mL, 5.1 mmol). After 2 hours the reaction was diluted with ethyl acetate and then washed with H_2O , sat. NH_4Cl , sat. NaHCO_3 and brine. Drying (MgSO_4) and concentration gave a yellow oil which was subjected to flash chromatography (silica, 20% ethyl acetate/hexanes) to give 122 as a waxy crystalline solid.

TLC R_f =0.31 (20% ethyl acetate/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.34 (m, 5H), 5.67 (m, 1H), 5.10 (s, 2H), 5.05 (m, 2H), 4.54 (m, 1H), 3.67 (s, 3H), 3.48 (m, 1H), 2.21 (m, 2H), 2.00-1.00 (m, 8H).

- 119 -

Preparation of 4-Amino,1-(propen-3-yl)cyclohexane
carboxylic acid methyl ester (123)

Trifluoroacetic acid (19 mL) was added to a mixture of 122 (0.63 g, 1.9 mmol) and anisole (0.41 mL, 3.8 mmol) at 0°C. After 5 min. the reaction mixture became homogeneous and removal of the cooling bath was followed by stirring overnight. Concentration, followed by flash chromatography (silica, 17:1:1 ethanol/NH₄OH/H₂O) gave 123 as a yellow oil.

TLC Rf=0.53 (30% ethyl acetate/hexanes).

Preparation of [2-Aza-3-oxo-[2.2.2]bicyclooct-4-yl]
prop-3-ene (124).

A solution of 123 (0.39g, 1.97 mmol) in toluene (10 mL) was heated at 170°C in a sealed tube overnight. The cooled dark reaction mixture was purified by flash chromatography (silica, 85% ethyl acetate/hexanes) to give 124 as a tan oil.

TLC Rf=0.30 (85% ethyl acetate/hexanes);

¹HMR (400 MHz, CDCl₃) δ 6.08 (m, 1H), 5.88 (m, 1H), 5.04 (m, 2H), 3.61 (m, 1H), 2.35 (d, J=7Hz, 2H), 1.80-1.50 (m, 8H).

Preparation of ([2-(N-Boc-piperidin-4-yl)ethyl]-2-
aza-3-oxo-[2.2.2]bicyclooct-4-yl)prop-3-ene (125).

Utilizing the procedure for converting 36a to 37a, 124 (0.18 g, 1.1 mmol) gave 125 (0.45 g, 100%) after flash chromatography (silica, 40% ethyl acetate/hexanes).

- 120 -

TLC Rf=0.36 (40% ethyl acetate/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 5.87 (m, 1H), 5.05 (m, 2H), 4.08 (m, 2H), 3.51 (m, 1H), 3.40 (t, J=8Hz, 2H), 2.67 (m, 2H), 2.34 (d, J=7Hz, 2H), 1.75-1.35 (m, 13H), 1.47 (s, 9H), 1.12 (m, 2H).

Preparation of 3-(1-[2-(N-Boc-piperidin-4-yl)ethyl]-2-aza-3-oxo-[2.2.2]bicyclooct-4-yl)acetic acid (126).

Utilizing the procedure for converting 14 to 15, 125 (0.42 g, 1.1 mmol) gave 126 (0.34 g, 76%) as a white sticky foam.

TLC Rf=0.58 (9.5:0.5:0.5 CH₂Cl₂/CH₃OH/AcOH).

Preparation of ([2-(N-Boc-piperidin-4-yl)ethyl]-2-aza-3-oxo-[2.2.2]bicyclooct-4-yl)acetyl-β-alanine tert-butyl ester (127).

Utilizing the procedure for converting 15 to 16, 126 (0.14g, 0.35 mmol) gave 127 (0.10 g, 55%) as a colorless oil after flash chromatography (silica, 6:1 CH₂Cl₂/acetone).

TLC Rf=0.52 (2:1 CH₂Cl₂/acetone); ¹H NMR (400 MHz, CDCl₃) δ 7.90 (m, 1H), 4.04 (m, 2H), 3.56 (m, 1H), 3.42 (m, 4H), 2.67 (m, 2H), 2.42 (t, J=7Hz, 2H), 1.76-1.34 (m, 13H), 1.46 (s, 18H), 1.12 (m, 2H).

Preparation of ([2-(Piperidin-4-yl)ethyl]-2-aza-3-oxo-[2.2.2]bicyclooct-4-yl)acetyl-β-alanine (128).

Utilizing the procedure for converting 40a to 41a, 127 (0.10 g, 0.19 mmol) gave 128 (29 mg, 39%) as a fluffy solid after flash chromatography (silica, 10:1.2:1.2 ethanol/H₂O/NH₄OH).

- 121 -

TLC Rf=0.17 (10:1:1 ethanol/NH₄OH/H₂O); ¹H
NMR (400 MHz, D₂O) δ 3.78 (m, 1H), 3.50-3.35 (m, 6H),
2.97 (m, 2H), 2.48 (s, 2H), 2.38 (t, J=7Hz, 2H), 2.02
(m, 2H), 1.78 (m, 6H), 1.58 (m, 5H), 1.42 (m, 2H).

5

Applicants hereby incorporate by reference
procedures for preparing compounds of the present
invention whereby guanidines are prepared from amines
and whereby amidines are prepared from corresponding
nitriles. Guanidines may be prepared from amines by
10 those having ordinary skill in the art upon reaction
with 3,5-dimethylpyrazole-1-carboxamidine nitrate
(Methods Enzymol., 25b, 558, 1972). Amidines may be
prepared from the corresponding nitrile by those
15 having ordinary skill in the art using procedures
demonstrated by Boere, R.T., et. al. J. Organomet.
Chem., 331(2), 161-7, 1987; and Fuks, R., Tetrahedron,
29 (14), 2147-51, 1973.

20


Utilizing the methodology demonstrated in
this invention, the following compounds, included in
Table I below, are exemplary of the compounds which
may be prepared according to this invention.

25


30

- 122 -


TABLE I



5




10




15

20



25



30

- 123 -

TABLE I (Cont'd)

	R^1	R^2
5		
10		
15		
20		
25		

30

- 124 -

In vivo Activity

The following protocols were used to determine in vivo activity in dogs of fibrinogen receptor antagonists of the present invention.

5 A mongrel dog of either sex (weighing 7.5 to 11.5 kg) is comfortably positioned in a nylon sling which exposes the legs and keeps the dog stationary. Five ml of blood is withdrawn from either saphenous or cephalic veins with a plastic syringe containing 10 0.5 ml of 3.8% citrate via a 19-gauge butterfly. An additional 1 ml of citrated blood is taken to measure whole blood platelet counts. Ex vivo platelet aggregations are done with the agonists ADP (10 μ M) and collagen (10 μ g/ml) both primed with 1 μ M 15 epinephrine. Platelet-rich plasma (PRP) is obtained by centrifuging the blood at 150 x g for 5 minutes. Platelet counts are adjusted to 200,000/mm³ with platelet-poor plasma.

20 Oral administration of a drug is done either as a gelatin capsule or a gastric lavage. For the gastric lavage method, 5 ml of the drug solution is administered to the dog through a feeding tube. Blood samples for ex vivo platelet aggregation are 25 taken at the following time points: 0, 20, 40, 70, 90, 150, 200, 250, 300, 350, 480 min. 24 hr. 30 hr, and 48 hr. At each time point, the remaining platelet-poor plasma is saved and frozen for drug levels. Three additional blood samples are taken at 30 30, 55, and 110 minutes after dosing for drug plasma levels.


- 125 -

For the intravenous infusion, blood samples for ex vivo platelet aggregation are taken at the following time points: 0, 30, 45, 60, 90 and 120 min into the infusion and 2, 5, 15, 30, 60, 90, 120, 180, 240, 300, 360, and 420 minutes after the infusion stops. At each time point, the remaining platelet-poor plasma is saved and frozen for drug levels. The drug is infused for 120 minutes at a constant rate of 0.1 ml/min.

For the intravenous bolus, 5 ml of the drug solution is administered quickly. Blood samples for ex vivo platelet aggregation are taken at 0, 1, 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 minutes after the bolus. At all time points, the remaining platelet-poor plasma was saved and frozen for drug levels.

In the oral and intravenous groups, blood collection times are recorded at each time point in order to determine drug plasma levels.

The following compound



was evaluated according to the procedures described above.

- 126 -

Inhibition of platelet aggregation (% of control) induced by intravenous infusion at rates of 10 µg/kg/min and 25 µg/kg/min was measured. Inhibition was nearly complete during infusion and partial inhibition existed for several hours after infusion cessation.

5

Inhibition of platelet aggregation (% of control) induced by single oral administration of 2 mg/kg was also measured. % Inhibition of platelet aggregation was greater than 50% for a period of eight hours.

10

15

20


25

30

- 127 -

WHAT IS CLAIMED IS:

1. A fibrinogen receptor antagonist of
Formula I:




wherein:


10

X is


15



20




25



30


- 128 -



where A=N and B= -CH₂-, or A= -CH- and B= N-R⁷;

15

Y is



30

- 129 -

Z is $-\text{CO}_2\text{R}^2$; $-\overset{\text{O}}{\underset{\text{OR}^2}{\text{P}}}-\text{OH}$; $-\overset{\text{O}}{\underset{\text{R}^{10}}{\text{P}}}-\text{OH}$;

where R^{10} is $\text{C}_{1-8}\text{alkyl}$, aryl, aryl $\text{C}_{1-8}\text{alkyl}$

5

u is $-\text{CH}-$, $-\text{C}-$, or $-\text{N}-$;

v is $-\text{CH}-$, $-\text{C}-$, or $-\text{N}-$;

10

R and R^1 are independently
hydrogen,

15

aryl, wherein aryl is defined as a mono- or polycyclic aromatic system comprised of 5 or 6 membered rings containing 0, 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen and sulfur; and phenylene, either unsubstituted or substituted, with one or more groups selected from hydroxyl, fluoro, chloro, bromo, iodo, cyano, trifluoromethyl, C_{1-3} alkoxy, $\text{C}_{1-5}\text{alkylcarbonyloxy}$, $\text{C}_{1-5}\text{alkoxycarbonyl}$, $\text{C}_{1-5}\text{alkyl}$, amino $\text{C}_{1-5}\text{alkyl}$, hydroxycarbonyl-
25 $\text{C}_{0-5}\text{alkyl}$, or hydroxycarbonyl $\text{C}_{1-5}\text{alkoxy}$, $\text{C}_{0-6}\text{alkyl}$, either unsubstituted or substituted, with one or more

30


- 130 -

groups selected from fluoro, chloro,
bromo, iodo, hydroxyl, C₁₋₅alkyl-
carbonyl(C₀₋₈alkyl)amino, arylC₁₋₅alkyl
carbonyl(C₀₋₈alkyl)amino, aryloxy,
5 C₁₋₁₀ alkoxy, C₁₋₅alkoxycarbonyl,
C₀₋₅alkylaminocarbonyl, C₁₋₅alkyl-
carbonyloxy, C₃₋₈ cycloalkyl, aryl,
exo, amino, C₁₋₆ alkyl, C₁₋₃alkylamino,
aminoC₁₋₃ alkyl, arylC₀₋₅alkylamino-
10 carbonyl, phenylC₁₋₃alkylamino, amino-
carbonyl-C₀₋₄alkyl, C₁₋₈alkylsulfonyl
(C₀₋₈alkyl)amino, aryl C₀₋₁₀alkyl-
sulfonyl(C₀₋₈alkyl)amino, arylC₀₋₈alkyl-
sulfonyl, C₀₋₈alkylsulfonyl, hydroxy-
15 carbonylC₀₋₅ alkyl, C₁₋₈alkyloxycarbonyl
(C₀₋₈alkyl)amino, arylC₀₋₁₀alkyloxy-
carbonyl(C₀₋₈alkyl)amino, C₀₋₈alkyl-
aminocarbonyl(C₀₋₈ alkyl) amino,
arylC₀₋₈alkylaminocarbonyl(C₀₋₈alkyl)-
20 amino, C₀₋₈alkylaminocarbonyloxy,
arylC₀₋₁₀alkylaminocarbonyloxy,
C₀₋₈alkylaminosulfonyl(C₀₋₈ alkyl)-
amino, arylC₀₋₈alkylaminosulfonyl(C₀₋₈-
alkyl)amino, C₀₋₈alkylaminosulfonyl, or
25 arylC₀₋₈-alkylaminosulfonyl; provided
that the carbon atom to which R or R¹
is attached bear only one heteroatom;

30

- 131 -

R² is hydrogen,
C₁₋₁₂alkyl, unsubstituted or substituted,
with one or more C₁₋₆alkyl groups,




5 where R⁹ = C₁₋₆alkyl, branched or
unbranched, or phenyl, and wherein R⁹, when
appearing more than once, can be the same
or different;

10 R⁷, R³ and R⁴ are independently
hydrogen,
C₁₋₁₂ alkyl, unsubstituted or substituted,
with one or more C₁₋₆ alkyl
groups, or

15 arylC₀₋₄alkyl, or
cyano,

provided that when R⁷ and R³
are independently cyano,



k is 1-4;

m is 1-4;

25 p is 1-6;

q is 0-2;

or the pharmaceutically acceptable salts thereof, or
optical isomer thereof.



30

- 132 -

2. A fibrinogen receptor antagonist of
formula 1 in Claim 1,

wherein:

5 X is $-\text{NR}^7\text{R}^3$, $-\overset{\text{NH}}{\underset{\text{||}}{\text{C}}}-\text{NR}^7\text{R}^3$,



25 where D = $-\overset{\text{O}}{\underset{\text{||}}{\text{C}}}-$, $-\text{S}(\text{O})_q$, or $-\text{O}-$;



30 Y is

- 133 -

3. A fibrinogen receptor antagonist of
Formula I in Claim 1,

wherein



X is




where D = -O-, -S-, or $\text{C}(=\text{O})$ -

Z is CO_2R^2

Y is



or



wherein n is 1, 2 or 3;

- 134 -

C_{0-6} alkyl either unsubstituted or substituted,
 with one or more groups selected from halogen,
 hydroxyl, C_{1-6} alkylsulfonylamino, aryl
 C_{0-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl,
 5 aryl C_{0-6} alkylsulfonyl, C_{1-5} alkylcarbonylamino,
 aryl C_{1-5} alkylcarbonylamino, aryloxy, C_{1-10}
 alkoxy, C_{1-5} alkoxycarbonyl, C_{0-5} alkylamino-
 carbonyl, C_{1-5} alkylcarbonyloxy, C_{3-8} cycloalkyl,
 aryl, oxo, amino, C_{1-6} alkyl, C_{1-3} alkylamino,
 10 amino C_{1-3} alkyl, aryl C_{0-5} alkylaminocarbonyl,
 phenyl C_{1-3} alkylamino, aminocarbonyl C_{0-4} alkyl,
 or hydroxycarbonyl C_{0-5} alkyl, provided that the
 carbon atom to which R or R^1 is attached bear
 only one heteroatom,

15 R^2 is hydrogen,
 C_{1-12} alkyl, unsubstituted or substituted,
 with one or more C_{1-6} alkyl groups,

$$-\text{CH}_2\overset{\text{O}}{\parallel}\text{CR}^9, -\overset{\text{R}^9}{\underset{|}{\text{CH}}}\overset{\text{O}}{\parallel}\text{CR}^9 \text{ or } -\overset{\text{CH}_3}{\underset{|}{\text{C}}}-\overset{\text{CH}_3}{\underset{|}{\text{O}}}-\overset{\text{O}}{\parallel}\text{C}-\text{R}^9$$
 20 where $R^9 = C_{1-6}$ alkyl, branched or
 unbranched, or phenyl;

R^7 , R^3 and R^4 are independently
 hydrogen,
 25 C_{1-3} alkyl, unsubstituted or substituted,
 with one or more C_{1-6} alkyl groups;

k is 1-4;

m is 1-4;

30 p is 1-3;

q is 0 or 2;



or the pharmaceutically acceptable salts thereof, or
 optical isomer thereof.

- 135 -

3. A fibrinogen receptor antagonist of
Formula I in Claim 1,

wherein




X is



where D = -O-, -S-, or $\text{---}\overset{\text{O}}{\parallel}\text{C---}$

Z is CO_2R^2

Y is



wherein n is 1, 2 or 3;

- 136 -

R and R¹ are independently chosen from phenyl, thiophene, imidazole, naphthyl, indole, indazole, thionaphthene, either unsubstituted or substituted, with hydroxy, halogen, hydroxy-carbonylC₀₋₅alkyl, C₁₋₃alkyl, either
5 unsubstituted or substituted, with one or more groups selected from aryl, aryloxy, C₁₋₁₀alkoxy, C₀₋₅alkylaminocarbonyl, arylC₀₋₅alkylaminocarbonyl, hydrogen, C₀₋₆alkyl, either unsubstituted or substituted, with one
10 or more groups selected from halogen, hydroxyl, C₁₋₅alkylcarbonylamino, aryl C₁₋₅alkylcarbonylamino, aryloxy, C₁₋₁₀alkoxy, C₁₋₅alkoxycarbonyl, C₀₋₅alkylaminocarbonyl, C₁₋₅alkylcarbonyloxy, C₃₋₈cycloalkyl, aryl, 15 oxo, amino, C₁₋₆alkyl, C₁₋₃alkylamino, amino C₁₋₃alkyl, arylC₀₋₅alkylaminocarbonyl, phenylC₁₋₃alkylamino, aminocarbonylC₀₋₄alkyl, or hydroxycarbonylC₀₋₅alkyl, provided that the carbon atom to which R or R¹ is attached bear
20 only one heteroatom;

R² is, hydrogen;

25 R⁷, R³ and R⁴ are hydrogen;

k is 1-2;

m is 1-4;



p is 2-4;

30 or the pharmaceutically acceptable salts thereof, or optical isomer thereof.

- 137 -


4. The compound of Claim 1 for use in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.

5. A compound of Claim 1 selected from the group consisting of:




- 138 -

5




10

15



20


25




30

- 139 -

5




10



15

20




25


30

- 140 -

5




10




15

20




25




30

- 141 -

5




10




15

20




25




30

- 142 -

5




10




15

20




25




30


- 143 -



5



10




15

or pharmaceutically acceptable salts thereof.

20

6. A compound of claim 5 which is:




25

30

or pharmaceutically acceptable salts thereof.

- 144 -


7. A compound of claim 5 which is:



10

or pharmaceutically acceptable salts thereof.

8. A compound of Claim 5 which is:




20

or pharmaceutically acceptable salts thereof.

9. A compound of Claim 5 which is:

25




30

or pharmaceutically acceptable salts thereof.

- 145 -

10. A compound of Claim 5 which is

5




10


or pharmaceutically acceptable salts thereof.

11. A compound of Claim 1 which is:


15



20




25




30

- 146 -

5



10



15 or pharmaceutically acceptable salts thereof.

12. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

13. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

14. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 1 in combination with a thrombolytic agent and a pharmaceutically acceptable carrier.

- 147 -

15. The composition of Claim 14, wherein the thrombolytic agent is a plasminogen activator or streptokinase.

5 16. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 1 in combination with an anticoagulant and pharmaceutically acceptable carrier.

10 17. The composition of Claim 16, wherein the anticoagulant is heparin or warfarin.

15 18. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

20 19. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with a thrombolytic agent and a pharmaceutically acceptable carrier.

25 20. The composition of Claim 18, wherein the thrombolytic agent is plasminogen activator or streptokinase.

30 21. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with an anticoagulant and pharmaceutically acceptable carrier.

- 148 -

22. The composition of Claim 21, wherein the anticoagulant is heparin or warfarin.

5 23. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

10 24. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with a thrombolytic agent and a pharmaceutically acceptable carrier.

15 25. The composition of Claim 24, wherein the thrombolytic agent is plasminogen activator or streptokinase.

20 26. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with an anticoagulant and pharmaceutically acceptable carrier.

27. The composition of Claim 26, wherein the anticoagulant is heparin or warfarin.

25 28. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with an antiplatelet agent and a pharmaceutically acceptable carrier.

30

- 149 -

29. The composition of Claim 28, wherein the antiplatelet agent is aspirin.

5 30. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 13.

10 31. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 13.

15 32. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 14.

20 33. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 16.

25 34. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 18.

30 35. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 19.

- 150 -

36. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition Claim 21.

5 37. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 23.

10 38. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 24.

15 39. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 26.

20 40. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 28.

25 41. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 1 in combination with two or more agents selected from a thrombolytic agent, an anticoagulant agent, and an antiplatelet agent and a pharmaceutically acceptable carrier.
30

- 151 -

42. The composition of Claim 41, wherein the thrombolytic agent is a plasminogen activator or streptokinase, the anticoagulant agent is heparin or warfarin, and the antiplatelet agent is aspirin.

5

43. A composition for preventing or treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 in combination with two or more agents selected from a thrombolytic agent, an anticoagulant agent, and an antiplatelet agent and a pharmaceutically acceptable carrier.

10

44. The composition of Claim 43, wherein the thrombolytic agent is a plasminogen activator or streptokinase, the anticoagulant agent is heparin or warfarin, and the antiplatelet agent is aspirin.

15

45. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 41.

20

46. A method for preventing or treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 43.

25

47. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising a compound of Claim 5 and a pharmaceutically acceptable carrier.

30

- 152 -

48. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 47.

5 49. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 5 and a pharmaceutically acceptable carrier.

10 50. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of claim 49.

15 51. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 5 and a pharmaceutically acceptable carrier.

20 52. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 51.

25 53. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compound of Claim 6 and a pharmaceutically acceptable carrier.

30 54. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 53.

- 153 -

55. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compound of Claim 6 and a pharmaceutically acceptable carrier.

5

56. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of claim 55.

10

57. A composition for preventing thrombus or embolus formation in a mammal, comprising the compound of Claim 6 and a pharmaceutically acceptable carrier.

15

58. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 57.

20

59. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compound of Claim 7 and a pharmaceutically acceptable carrier.

25

60. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 59.

30

- 154 -

61. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compound of Claim 7 and a pharmaceutically acceptable carrier.

5 62. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of claim 61.

10 63. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 7 and a pharmaceutically acceptable carrier.

15 64. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 63.

20 65. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compound of Claim 8 and a pharmaceutically acceptable carrier.

25 66. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 65.

30

- 155 -

67. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compound of Claim 8 and a pharmaceutically acceptable carrier.

5

68. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of claim 67.

10

69. A composition for preventing thrombus or embolus formation in a mammal, comprising the compound of Claim 8 and a pharmaceutically acceptable carrier.

15

70. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 69.

20

71. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compound of Claim 9 and a pharmaceutically acceptable carrier.

25

72. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 71.

30

- 156 -

73. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compound of Claim 9 and a pharmaceutically acceptable carrier.

5 74. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of claim 73.

10 75. A composition for preventing thrombus or embolus formation in a mammal, comprising the compound of Claim 9 and a pharmaceutically acceptable carrier.

15 76. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 75.

20 77. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compound of Claim 10 and a pharmaceutically acceptable carrier.

25 78. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 77.

30

- 157 -

79. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compound of Claim 10 and a pharmaceutically acceptable carrier.

5

80. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 79.

10

81. A composition for preventing thrombus or embolus formation in a mammal, comprising the compound of Claim 10 and a pharmaceutically acceptable carrier.

15

82. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 81.

20

83. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal comprising the compounds of Claim 11 and a pharmaceutically acceptable carrier.

25

84. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 83.

30

- 158 -

85. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising the compounds of Claim 11 and a pharmaceutically acceptable carrier.

5

86. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 85.

10

87. A composition for preventing thrombus or embolus formation in a mammal, comprising the compounds of Claim 11 and a pharmaceutically acceptable carrier.

15

88. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 87.

20

89. A method for inhibiting mammalian fertilization in a mammal comprising administering to the mammal a compound of Claim 1.

25

30

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US92/03463

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * <small>According to International Patent Classification (IPC) or to both National Classification</small> INT. Class C07D 211/18, 40/86 401/06 417/06 U.S. CL 546/186, 193, 208, 209, 210 514/316, 318, 326														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ?</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">US</td> <td style="padding: 5px;">546/186, 193, 208, 209, 210 514/316, 318, 326</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *</div>			Classification System	Classification Symbols	US	546/186, 193, 208, 209, 210 514/316, 318, 326								
Classification System	Classification Symbols													
US	546/186, 193, 208, 209, 210 514/316, 318, 326													
III. DOCUMENTS CONSIDERED TO BE RELEVANT * <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; text-align: left; padding: 5px;">Category *</th> <th style="width: 60%; text-align: left; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; text-align: left; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0,384,362 (ALIG ET AL) 19 February 1990 See entire document.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-89</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0,352,249 (TJOENG et al) 19 July 1989 See entire document.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-89</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 4,064,255 (CHAMPEIX et al.) 20 December 1977 See entire document.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-89</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A, 0,384,362 (ALIG ET AL) 19 February 1990 See entire document.	1-89	A	EP, A, 0,352,249 (TJOENG et al) 19 July 1989 See entire document.	1-89	A	US, A, 4,064,255 (CHAMPEIX et al.) 20 December 1977 See entire document.	1-89
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
A	EP, A, 0,384,362 (ALIG ET AL) 19 February 1990 See entire document.	1-89												
A	EP, A, 0,352,249 (TJOENG et al) 19 July 1989 See entire document.	1-89												
A	US, A, 4,064,255 (CHAMPEIX et al.) 20 December 1977 See entire document.	1-89												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of the Actual Completion of the International Search 01 July 1992 </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of Mailing of this International Search Report 09 JUL 1992 </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;"> International Searching Authority ISA/US </td> <td style="vertical-align: top; padding: 5px;"> Signature of Authorized Officer M.B. Hydorn </td> </tr> </table>			Date of the Actual Completion of the International Search 01 July 1992	Date of Mailing of this International Search Report 09 JUL 1992	International Searching Authority ISA/US	Signature of Authorized Officer M.B. Hydorn								
Date of the Actual Completion of the International Search 01 July 1992	Date of Mailing of this International Search Report 09 JUL 1992													
International Searching Authority ISA/US	Signature of Authorized Officer M.B. Hydorn													